(19)
(11)EP 3 583 102 B1

(12)EUROPEAN PATENT SPECIFICATION

(45)Mention of the grant of the patent:
04.11.2020 Bulletin 2020/45

(21)Application number: 18706231.0

(22)Date of filing:  14.02.2018
(51)International Patent Classification (IPC): 
C07D 311/16(2006.01)
C08F 124/00(2006.01)
A61F 2/16(2006.01)
C07D 335/06(2006.01)
C08F 128/06(2006.01)
(86)International application number:
PCT/EP2018/053629
(87)International publication number:
WO 2018/149855 (23.08.2018 Gazette  2018/34)

(54)

HYDROPHOBIC COMPOUNDS FOR OPTICALLY ACTIVE DEVICES

HYDROPHOBE VERBINDUNGEN ZUR HERSTELLUNG VON OPTISCH AKTIVEN VORRICHTUNGEN

COMPOSÉS HYDROPHOBES POUR DISPOSITIFS OPTIQUEMENT ACTIFS


(84)Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30)Priority: 15.02.2017 EP 17156321

(43)Date of publication of application:
25.12.2019 Bulletin 2019/52

(73)Proprietor: Merck Patent GmbH
64293 Darmstadt (DE)

(72)Inventors:
  • DOBELMANN-MARA, Lars
    64295 Darmstadt (DE)
  • RIEDMUELLER, Stefan
    60488 Frankfurt Am Main (DE)
  • SCHRAUB, Martin
    64665 Alsbach-Haehnlein (DE)


(56)References cited: : 
WO-A1-2009/074521
  
  • SCHRAUB MARTIN ET AL: "Photoinduced refractive index changes of 3-phenyl-coumarin containing polymers for ophthalmic applications", EUROPEAN POLYMER JOURNAL, vol. 51, 2014, pages 21-27, XP028810223, ISSN: 0014-3057, DOI: 10.1016/J.EURPOLYMJ.2013.11.014 cited in the application
  
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).


Description

Field of the Invention



[0001] The present invention relates to novel compounds, particularly to compounds comprising a photoactive unit, said novel compounds being particularly suitable for compositions and ophthalmic devices as well as to compositions and ophthalmic devices comprising such compounds.

Background of the Invention



[0002] Cataract is a general term for an affection of the eye that leads to a loss of vision and in the extreme to blindness by clouding of the normally clear lens of the eye. It is the major cause of blindness in the world, affecting more than 100 million people. Due to the fact that its major cause is age and the population's average age is increasing, it is expected that the number of cataracts will continue to increase substantially in the future.

[0003] Effective treatment of cataract is only possible by surgical intervention, whereby the natural lens of the eye is removed through an incision in the cornea and replaced with an artificial lens, often also referred to as "intraocular lens". In preparation of surgery current state-of-the-art surgical methods employ eye mapping so as to approximate the refractive power best suited to the respective patient.

[0004] Even though cataract surgery is one of the most widely used and safest surgical procedures it is not without specific post-surgery problems. It frequently happens that the refractive power of the implanted intraocular lens (IOL) is insufficient for restoring good vision. Such problems may, for example, be caused by changes in eye geometry as consequence of the surgery as well as irregular wound healing and positioning errors that result in the artificial lens not having the optimal optical properties. As a result the patient will still require corrective vision aids, e.g. glasses, to be able to see correctly. In some cases the resulting refractive power of the implanted artificial lens is so far removed from the required refractive power that further surgery will be required. Particularly for aged persons this is not desirable because the body's capability for healing is reduced with increasing age. Furthermore, there is the risk of attracting endophthalmitis, an inflammation of the eye, which can even lead to a complete loss of vision or worse, loss of the eye.

[0005] There is therefore a need in the health sector for optically active devices, and particularly for artificial intraocular lenses, that would allow for non-invasive adjustment of refractive power after implantation of the lens, thereby preferably further reducing the need for post-surgery vision aids.

[0006] Some developments in this sense have already been made, as for example evidenced by WO 2007/033831 A1, WO 2009/074520 A2 or US 2010/0324165 A1.

[0007] EP 2837671 A describes liquid crystal media comprising acrylates or methacrylates such as the compounds RM-49 to RM-52.

[0008] WO 2010/049044 A1 describes liquid crystal media comprising acrylates or methacrylates such as for example (3-(4-methoxyphenyl)-2-oxo-2H-chromen-7-yl 2-methacrylate).

[0009] WO 2011/098224 A1 describes liquid crystal media comprising acrylates or methacrylates such as the compounds RM-18 to RM-21.

[0010] WO 2016/200401 A1 describes liquid crystal materials having photoalignment properties.

[0011] M. Schraub et al, European Polymer Journal 51 (2014) 21-27 describes the photochemistry of 3-phenyl-coumarin containing polymethacrylates.

[0012] Poly(methyl methacrylate) (PMMA) intraocular lenses (IOLs) that were coated with Teflon AF®, an amorphous, transparent, and highly hydrophobic fluorocarbon polymer is known from Jean-Marc Legeais, J Cataract Refract Surg. 1998, 24, 371-379. Teflon AF® (Dupont de Nemours) is a poly(tetra-fluoroethylene co-hexafluoro-propyl-2 cyclodethoxydifluoroethylene). Constituted entirely of high-energy bonds, it is stable at temperatures up to 260°C and chemically very resistant. The refractive index is 1.32. It transmits light from 200 to 2000 nm with a constant light absorption below 5%. The contact angle with water is 129 degrees. The surface modification is described using a PMMA IOL (model 808A, Kabi Pharmacia Production B.V.) having an overall diameter of 12.0 mm and optic diameter of 6.5 mm which is coated by immersing the lense in a 5% solution of Teflon AF in a fluorocarbon solvent (C8F18) for 3 seconds and then placing it at a temperature of 37°C to evaporate the solvent. As a result, the surface of the PMMA IOL was completely coated with Teflon AF.

[0013] Eun-Ho Sohn et al describe surface properties of poly(methyl methacrylate) (PMMA) films using poly(perfluoromethyl methacrylate)s (PFMMAs) with short perfluorinated side chains. 2,2,2-Trifluoroethyl methacrylate, 1,1,1,3,3,3-hexafluoroisopropyl methacrylate, 2,2,3,3,3-pentafluoropropyl methacrylate, 2,2,3,3,4,4,4-heptafluorobutyl methacrylate were prepared by radical polymerization of the corresponding monomers. Film preparation is reported with PMMA, PFMMA and their blends.

[0014] However, the compounds disclosed therein suffer from being too stiff and too brittle so that they can't be rolled or folded and are thus not fit to be implanted by state of the art cataract surgical methods, particularly by state of the art micro-incision cataract surgical methods.

[0015] Consequently, it is an objective of the present application to provide for novel compounds suitable for ophthalmic devices.

[0016] It is also an objective of the present application to provide for compounds, the optical properties of which may be changed, preferably by non-invasive techniques.

[0017] It is a further objective of the present application to provide for novel compounds having advantages over currently known compounds, preferably in combination with being suitable for ophthalmic devices.

[0018] Advantages such as better flexibility and objectives of the compounds of the present application will be evident to the skilled person from the following detailed description as well as from the examples.

Summary of the Invention



[0019] The present inventors have now found that the above objects may be attained either individually or in any combination by the compounds and ophthalmic devices of the present application.

[0020] The invention relates to compounds of formula (I')

wherein
X
is O, S or NR0,
X0
is O or S,
Y
is O, S or a bond,
-[B]-
is selected from the group consisting of formulae (B-1), (B-3), (B-8) and (B-9),



R
is at each occurrence independently selected from the group consisting of H, F, a linear or branched alkyl group having 1 to 4 C atoms or a linear or branched partially or fully fluorinated alkyl group having 1 to 4 C atoms,
R'
is at each occurrence independently selected from the group consisting of H, F, a linear or branched, non-halogenated, partially or completely halogenated alkyl group having 1 to 20 C atoms, a non-halogenated, partially or completely halogenated cycloalkyl group having 3 to 6 C atoms, a linear or branched, non-halogenated, partially or completely halogenated alkoxy group having 1 to 20 C atoms, a linear or branched, non-halogenated, partially or completely halogenated thioalkyl group having 1 to 20 C atoms,
R0
is at each occurrence independently selected from the group consisting of a linear or branched alkyl group having 1 to 10 C atoms or a cycloalkyl group having 3 to 6 C atoms,
R1
is a polymerizable group of formula (5),

wherein
X11 is C(=O)O,
R8 is H or methyl,
R9, R10 are H,
c is 1,
-R2-
is -(C(R)2)o-, or -(C(R)2)p-X8-(C(R)2)q-(X9)s-(C(R)2)r-(X10)t-(C(R)2)u-, wherein at least one R is F or a linear or branched partially or fully fluorinated alkyl group having 1 to 4 C atoms, or
a cycloalkylene group having 5 or 6 C atoms which is substituted with at least one R which is F or a linear or branched partially or fully fluorinated alkyl group having 1 to 4 C atoms,
o
is selected from the group consisting of 1 to 20,
X8, X9, X10
are at each occurrence independently O, S or NR0,
s, t
is 0 or 1,
p, q
are at each occurrence independently selected from the group consisting of 1 to 10,
r, u
are at each occurrence independently selected from the group consisting of 0 to 10, wherein the overall number of atoms for -(C(R)2)p-X8-(C(R)2)q-(X9)s-(C(R)2)r-(X10)t-(C(R)2)u- is up to 20 atoms,
R3, R4, R5, R6
are at each occurrence independently R',
R7
is R'.


[0021] In the following, the compounds of formula (I') are also called compounds of formula (I).

[0022] The invention relates further to compositions comprising at least one of said compounds of formula (I) and/or their polymerized forms as well as to articles comprising at least one polymerized compound of formula (I).

[0023] In addition, the invention relates to a process for forming such article, said process comprising the steps of
  • providing a composition comprising at least one compound of formula (I) and/or an oligomer or polymer as described before;
subsequently forming the article of said composition.

[0024] Furthermore, the invention relates to a process for changing the optical properties of an article according to the invention, said process comprising the steps of
  • providing an article comprising at least one polymerized compound of formula (I), and
  • subsequently exposing said article to irradiation having a wavelength of at least 200 nm and at most 1500 nm.

Detailed Description of the Invention



[0025] The compounds of formula (I) and all preferred embodiments of compounds of formula (I) according to the present invention include all stereoisomers or racemic mixtures.

[0026] The compounds of formula I provide several advantages over prior art materials
  • by adding a linker -[B]- with a specific substitution pattern to the 1-benzopyran-2-one, 1-benzopyran-2-thione, thiochromene-2-one, thiochromene-2-thione, quinolin-2-one or quinolin-2-thione ring system their melting point or glass transition temperature decrease and π stacking is disturbed, thus becoming better foldable or bendable,
  • by incorporating at least one F atom or at least one partially or fully fluorinated alkyl group they develop a non-sticky behavior with characteristic surfactant properties; through their non-stickiness the compounds also show a smoother behavior in a physiological environment.


[0027] Polymers that are foldable at room temperature generally exhibit glass transition temperatures (Tg) lower than room temperature (ca. 21 °C). They are easily deformable at this temperature without causing physical damage to the polymer, for example by inducing creep, stress or fissures. For polymers in intraocular lenses, Tgs of less than or equal to 15 °C are preferred.

[0028] Polymers used in intraocular lens manufacturing have preferably relative high refractive indices, which enable the fabrication of thinner intraocular lenses. Preferably, the polymer used in an intraocular lens will have a refractive index greater than about 1.5 and presently most preferably greater than about 1.55.

[0029] In case an asterisk ("*") is used within the description of the present invention, it denotes a linkage to an adjacent unit or group or, in case of a polymer, to an adjacent repeating unit or any other group.

[0030] A linear or branched alkyl group having 1 to 10 C atoms denotes an alkyl group having 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 C atoms, for example methyl, ethyl, iso-propyl, n-propyl, iso-butyl, n-butyl, tert-butyl, n-pentyl, 1-, 2- or 3-methylbutyl, 1,1-, 1,2- or 2,2-dimethylpropyl, 1-ethylpropyl, n-hexyl, n-heptyl, n-octyl, ethylhexyl, n-nonyl or n-decyl. A linear or branched alkyl group having 1 to 20 C atoms include all examples for a linear or branched alkyl group having 1 to 10 C atoms including any alkyl group having 11, 12, 13, 14, 15, 16, 17, 18, 19 and 20 C atoms such as n-undecyl, n-dodecyl, n-tridecyl, n-tetradecyl, n-pentadecyl, n-hexadecyl, n-heptadecyl, n-octadecyl, n-nonadecyl and n-eicosyl.

[0031] The term partially halogenated alkyl group denotes that at least one H atom of the alkyl group is replaced by F, Cl, Br or I. Preferably, the alkyl group is partially fluorinated meaning that at least one H atom of the alkyl group is replaced by F.

[0032] The term completely halogenated alkyl group denotes that all H atoms of the alkyl group are replaced by F, Cl, Br and/or I. Preferably, the alkyl group is completely fluorinated meaning that all H atoms of the alkyl group are replaced by F. A preferred completely fluorinated alkyl group is trifluoromethyl.

[0033] The term halogenated or preferably fluorinated corresponds additionally to other groups such as a halogenated cycloalkyl group, a halogenated alkoxy group or a halogenated thioalkyl group.

[0034] A cycloalkyl group having 3 to 6 C atoms includes cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl which may be partially or completely halogenated or fluorinated as explained before.

[0035] A linear or branched alkoxy group having 1 to 20 C atoms denotes an O-alkyl group having 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 C atoms, for example methoxy, ethoxy, iso-propoxy, n-propoxy, iso-butoxy, n-butoxy, tert-butoxy, n-pentyloxy, 1-, 2- or 3-methylbutyloxy, 1,1-, 1,2- or 2,2-dimethylpropoxy, 1-ethylpropoxy, n-hexyloxy, n-heptyloxy, n-octyloxy, ethylhexyloxy, n-nonyloxy, n-decyloxy, n-undecyloxy, n-dodecyloxy, n-tridecyloxy, n-tetradecyloxy, n-pentadecyloxy, n-hexadecyloxy, n-heptadecyloxy, n-octadecyloxy, n-nonadecyloxy and n-eicosyloxy which may be partially or completely halogenated or preferably may be partially or completely fluorinated. A preferred completely fluorinated alkoxy group is trifluoromethoxy.

[0036] A linear or branched thioalkyl group having 1 to 20 C atoms denotes a S-alkyl group having 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 C atoms, for example thiomethyl, 1-thioethyl, 1-thio-iso-propyl, 1-thio-n-propoyl, 1-thio-iso-butyl, 1-thio-n-butyl, 1-thio-tert-butyl, 1-thio-n-pentyl, 1-thio-1-, -2- or -3-methylbutyl, 1-thio-1,1-, -1,2- or -2,2-dimethylpropyl, 1-thio-1-ethylpropyl, 1-thio-n-hexyl, 1-thio-n-heptyl, 1-thio-n-octyl, 1-thio-ethylhexyl, 1-thio-n-nonyl, 1-thio-n-decyl, 1-thio-n-undecyl, 1-thio-n-dodecyl, 1-thio-n-tridecyl, 1-thio-n-tetradecyl, 1-thio-n-pentadecyl, 1-thio-n-hexadecyl, 1-thio-n-heptadecyl, 1-thio-n-octadecyl, 1-thio-n-nonadecyl and 1-thio-n-eicosyl which may be partially or completely halogenated or preferably may be partially or completely fluorinated. A preferred completely fluorinated thioether group is trifluoromethyl thioether.

[0037] Preferred alkyl and alkoxy radicals have 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 C atoms.

[0038] A polymerisable group is a group which can be subject to or can undergo polymerization thus forming an oligomer or a polymer.

[0039] Polymerization is the process of taking individual monomers and chaining them together to make longer units. These longer units are called polymers. The compounds of formula (I) as described before and preferably described below are suitable monomers.

[0040] Within the gist of the invention, the polymerizable group R1 once oligomerized or polymerized thus forms or is part of the backbone of the oligomer or polymer comprising polymerized compounds of formula (I). Suitable polymerizable groups contain at least one double bond or at least one triple bond thus forming polymers where the linking is formed via carbon-carbon bonds.

[0041] R1 represents therefore a polymerizable group according to formula (5),

wherein

X11 is C(=O)O,

R8 is H or methyl,

R9, R10 are H,

c is 1.



[0042] Particularly preferred polymerizable groups are described below.

[0043] Aryl with 6 to 14 C atoms is an aryl group preferably selected from the group consisting of phenyl, naphthyl or anthryl, particularly preferably phenyl.

[0044] The linker -[B]- is selected from the group of formulae (B-1), (B-3), (B-8) and (B-9),





wherein R' has a meaning as described before or preferably described below.

[0045] Within the compounds of formula (I), it is preferred to select the linker of formula (B-1) and R' has at each occurrence independently a meaning as described before or preferably described below.

[0046] R' is at each occurrence independently selected from the group consisting of H, F, a linear or branched, non-halogenated, partially or completely halogenated alkyl group having 1 to 20 C atoms, a non-halogenated, partially or completely halogenated cycloalkyl group having 3 to 6 C atoms, a linear or branched, non-halogenated, partially or completely halogenated alkoxy group having 1 to 20 C atoms, a linear or branched, non-halogenated, partially or completely halogenated thioalkyl group having 1 to 20 C atoms.

[0047] It is preferred that at least one R' in -[B]- as described before or preferably described before is different from H and is selected from the group consisting of F, a linear or branched, non-halogenated, partially or completely halogenated alkyl group having 1 to 20 C atoms, a non-halogenated, partially or completely halogenated cycloalkyl group having 3 to 6 C atoms, a linear or branched, non-halogenated, partially or completely halogenated alkoxy group having 1 to 20 C atoms, a linear or branched, non-halogenated, partially or completely halogenated thioalkyl group having 1 to 20 C atoms. It is particularly preferred that at least two substituents R' are different from H and are independently selected from the group consisting of F, a linear or branched, non-halogenated, partially or completely halogenated alkyl group having 1 to 20 C atoms, a non-halogenated, partially or completely halogenated cycloalkyl group having 3 to 6 C atoms, a linear or branched, non-halogenated, partially or completely halogenated alkoxy group having 1 to 20 C atoms, a linear or branched, non-halogenated, partially or completely halogenated thioalkyl group having 1 to 20 C atoms.

[0048] With regard to said substituent R', R' is at each occurrence independently preferably selected from the group consisting of H, F, a linear or branched, non-halogenated, partially or completely halogenated alkyl group having 1 to 10 C atoms, a linear or branched, non-halogenated and a partially or completely halogenated alkoxy group having 1 to 10 C atoms.

[0049] It is preferred that at least one R' in -[B]- as described before or preferably described before is different from H and is selected from the group consisting of F, a linear or branched, non-halogenated, partially or completely halogenated alkyl group having 1 to 10 C atoms, a linear or branched, non-halogenated and a partially or completely halogenated alkoxy group having 1 to 10 C atoms.

[0050] It is particularly preferred that at least two substituents R' are different from H and are independently selected from the group consisting of F, a linear or branched, non-halogenated, partially or completely halogenated alkyl group having 1 to 10 C atoms, a linear or branched, non-halogenated and a partially or completely halogenated alkoxy group having 1 to 10 C atoms.

[0051] R' is at each occurrence independently particularly preferably selected from the group consisting of H, F, methyl, ethyl, n-propyl, n-butyl, n-pentyl, n-hexyl, n-heptyl, n-octyl, trifluoromethyl, pentafluoroethyl, heptafluoropropyl, methoxy, ethoxy, propoxy, trifluoromethoxy and pentafluoroethoxy.

[0052] R' is at each occurrence independently very particularly preferably selected from the group consisting of H, F, ethyl, n-pentyl, trifluoromethyl, methoxy and trifluoromethoxy.

[0053] Therefore, the invention is further directed to compounds of formula (I) as described before where -[B]- corresponds to formulae (B-1), (B-3), (B-8) or (B-9), wherein at least one R' is not H.

[0054] As described before, the substituents R3, R4, R5 and R6 are at each occurrence independently R' where R' has a meaning or a preferred or particularly preferred meaning as described before.

[0055] R5 is preferably H or F. R5 is particularly preferably H.

[0056] As described before, the substituent R7 corresponds to R' wherein R' has a meaning or a preferred or particularly preferred meaning as described before. Preferably R7 corresponds to R' which is not H and has a meaning as described before or preferably described before or below.

[0057] In all cases when R' is preferably not H, it is selected from the preferred group consisting of F, methyl, ethyl, n-propyl, n-butyl, n-pentyl, n-hexyl, n-heptyl, n-octyl, trifluoromethyl, pentafluoroethyl, heptafluoropropyl, methoxy, ethoxy, propoxy, trifluoromethoxy and pentafluoroethoxy or from the particular preferred group consisting of F, ethyl, n-pentyl, trifluoromethyl, methoxy and trifluoromethoxy.

[0058] Therefore, the invention is further directed to compounds of formula (I) as described before where -[B]- corresponds to formulae (B-1), (B-3), (B-8) or (B-9), wherein at least one R' is not H and R7 is not H.

[0059] Compounds of formula (I) with linkers -[B]- as defined before or preferably defined before with the described or preferred substitution pattern on the linker -[B]- and its substituents R3, R4, R5 and R6 as described before or preferably described before are based on a 1-benzopyran-2-one ring system (coumarin or chromene-2-one) in case both X and X0 are O.

[0060] Compounds of formula (I) with linkers -[B]- as defined before or preferably defined before with the described or preferred substitution pattern on the linker -[B]- and its substituents R3, R4, R5 and R6 as described before or preferably described before are based on a 1-benzopyran-2-thione ring system (thiocoumarin or chromene-2-thione) in case X is O and X0 is S.

[0061] Compounds of formula (I) with linkers -[B]- as defined before or preferably defined before with the described or preferred substitution pattern on the linker -[B]- and its substituents R3, R4, R5 and R6 as described before or preferably described before are based on a thiochromene-2-one ring system in case X is S and X0 is O.

[0062] Compounds of formula with linkers -[B]- as defined before or preferably defined before with the described or preferred substitution pattern on the linker -[B]- and its substituents R3, R4, R5 and R6 as described before or preferably described before are based on a thiochromene-2-thione ring in case both X and X0 are S.

[0063] Compounds of formula with linkers -[B]- as defined before or preferably defined before with the described or preferred substitution pattern on the linker -[B]- and its substituents R3, R4, R5 and R6 as described before or preferably described before are based on a quinolin-2-one ring system in case X is NRo and X0 is O and R0 is independently selected from the group consisting of a linear or branched alkyl group having 1 to 10 C atoms or a cycloalkyl group having 3 to 6 C atoms.

[0064] Compounds of formula with linkers -[B]- as defined before or preferably defined before with the described or preferred substitution pattern on the linker -[B]- and its substituents R3, R4, R5 and R6 as described before or preferably described before are based on a quinolin-2-thione ring system in case X is NR0 and X0 is S and R0 is independently selected from the group consisting of a linear or branched alkyl group having 1 to 10 C atoms or a cycloalkyl group having 3 to 6 C atoms.

[0065] R0 is at each occurrence independently preferably methyl, ethyl, iso-propyl, 2-methyl-propyl, n-butyl, n-pentyl, 4-methyl-pentyl or cyclopropyl.

[0066] In case X is NR0, R0 is particularly preferably ethyl, iso-propyl, 2-methyl-propyl, n-pentyl or 4-methyl-pentyl.

[0067] In case X8, X9 or X10 is NR0, R0 is particularly preferably methyl. Compounds of formula with linkers and substituents as described before or preferably described before or below are preferred when X is O or S.

[0068] Compounds of formula with linkers and substituents as described before or preferably described before or below are particularly preferred when X0 is O and X is O or S.

[0069] Compounds of formula with linkers and substituents as described before or preferably described before or below are very particularly preferred when X is O and X0 is O.

[0070] The compounds of formula (I) as described before or preferably described before contain one polymerizable group R1. Such compounds can be preferably used as monomers for the preparation of a blank which may be transformed to an ophthalmic device such as an eye-implant or specifically an intraocular lens or to the ophthalmic device as such as described before.

[0071] Compounds of formula (I') with linkers -[B]- and substituents as described before or preferably described before have a polymerizable group as described before or preferably described before or below and have one linking element Y-R2.

[0072] Y is O, S or a bond.

[0073] The linking element -R2- is selected from the group consisting of -(C(R)2)o-wherein at least one R is F or a linear or branched partially or fully fluorinated alkyl group having 1 to 4 C atoms, -(C(R)2)p-X8-(C(R)2)q-(X9)s-(C(R)2)r-(X10)t-(C(R)2)u-, wherein at least one R is F or a linear or branched partially or fully fluorinated alkyl group having 1 to 4 C atoms and a cycloalkylene group having 5 or 6 C atoms which is substituted with at least one R which is F or a linear or branched partially or fully fluorinated alkyl group having 1 to 4 C atoms and o is selected from the group consisting of 1 to 20, X8, X9 and X10 are at each occurrence O, S or NR0, s and t are at each occurrence independently 0 or 1, p and q are at each occurrence independently selected from the group consisting of 1 to 10, r and u are at each occurrence independently selected from the group consisting of 0 to 10, wherein the overall number of atoms for -(C(R)2)p-X8-(C(R)2)q-(X9)s-(C(R)2)r-(X10)t-(C(R)2)u-, is up to 20 C atoms.

[0074] Preferably, the linking element -R2- is selected from the group consisting of -(C(R)2)o- wherein at least two substituents R are F or a linear or branched partially or fully fluorinated alkyl group having 1 to 4 C atoms, -(C(R)2)p-X8-(C(R)2)q-(X9)s-(C(R)2)r-(X10)t-(C(R)2)u-, wherein at least two substituents R are F or a linear or branched partially or fully fluorinated alkyl group having 1 to 4 C atoms and a cycloalkylene group having 5 or 6 C atoms which is substituted with at least one R which is F or a linear or branched partially or fully fluorinated alkyl group having 1 to 4 C atoms and o, X8, X9, X10, s, t, p, q, r and u have a meaning as described or preferably described before or below.

[0075] R is at each occurrence independently selected from the group consisting of H, F, a linear or branched alkyl group having 1 to 8 C atoms or a linear or branched partially or fully fluorinated alkyl group having 1 to 4 C atoms.

[0076] R is preferably at each occurrence independently selected from the group consisting of H, F, methyl, ethyl, n-propyl, isopropyl, n-butyl, n-pentyl, isobutyl, ethylhexyl, 2,2,2-trifluoroethyl, 3,3,3-trifluoropropyl, 2,2,3,3,3-pentafluoropropyl, trifluoromethyl, pentafluoroethyl, heptafluoropropyl and nonafluorobutyl. R is particularly preferably at each occurrence independently H, F, methyl, 2,2,2-trifluoroethyl or trifluoromethyl.

[0077] Preferably, o is selected from the group consisting of 3, 4, 5, 6, 7, 8, 9, 10, 11 and 12. Particularly preferably, o is selected from the group consisting of 8 to 12.

[0078] Preferably, s is 1.

[0079] Preferably t is 0 or 1.

[0080] Preferably, X8, X9 and X10 are O.

[0081] Preferably, p and u are each independently 1, 3, 3, 4, 5 or 6, particularly preferably 1 or 2.

[0082] Preferably, q and r are each independently 1, 2 or 3, particularly preferably 1.

[0083] Suitable examples for -R2- are -(CF2)-(CH2)-, -(CH2)-(CF2)-, -(CH2)-(CF2)-(CH2)-, -(CH2)-(CF2)-(CH2)2-,-(CH2)-(CF2)-(CH2)3-, -(CH2)-(CF2)-(CH2)4-, -(CH2)-(CF2)-(CH2)5-, -(CH2)-(CF2)-(CH2)6-, -(CH2)-(CF2)-(CH2)7-, -(CH2)-(CF2)-(CH2)8-, -(CH2)-(CF2)-(CH2)9-, -(CH2)-(CF2)-(CH2)10-, -(CH2)2-(CF2)-(CH2)-, -(CH2)3-(CF2)-(CH2)-,-(CH2)4-(CF2)-(CH2)-, -(CH2)5-(CF2)-(CH2)-, -(CH2)6-(CF2)-(CH2)-, -(CH2)7-(CF2)-(CH2)-, -(CH2)8-(CF2)-(CH2)-, -(CH2)9-(CF2)-(CH2)-, -(CH2)10-(CF2)-(CH2)-, -(CH2)2-(CF2)-(CH2)2-, -(CH2)3-(CF2)-(CH2)3-, -(CH2)4-(CF2)-(CH2)4-, -(CH2)5-(CF2)-(CH2)5-, -(CH2)2-(CF2)-(CH2)-, -(CH2)2-(CF2)-(CH2)3-,-(CH2)2-(CF2)-(CH2)4-, -(CH2)2-(CF2)-(CH2)5-, -(CH2)2-(CF2)-(CH2)6-, -(CH2)2-(CF2)-(CH2)7-, -(CH2)2-(CF2)-(CH2)8-, -(CH2)2-(CF2)-(CH2)9-, -(CH2)3-(CF2)-(CH2)-, -(CH2)3-(CF2)-(CH2)2-, -(CH2)3-(CF2)-(CH2)4-, -(CH2)3-(CF2)-(CH2)5-, -(CH2)3-(CF2)-(CH2)6-, -(CH2)3-(CF2)-(CH2)7-, -(CH2)3-(CF2)-(CH2)8-, -(CH2)4-(CF2)-(CH2)-, -(CH2)4-(CF2)-(CH2)2-, -(CH2)4-(CF2)-(CH2)3-, -(CH2)4-(CF2)-(CH2)5-, -(CH2)4-(CF2)-(CH2)6-, -(CH2)4-(CF2)-(CH2)7-, -(CH2)5-(CF2)-(CH2)-, -(CH2)5-(CF2)-(CH2)2-, -(CH2)5-(CF2)-(CH2)3-, -(CH2)5-(CF2)-(CH2)4-, -(CH2)5-(CF2)-(CH2)6-, -(CH2)6-(CF2)-(CH2)-, -(CH2)6-(CF2)-(CH2)2-, -(CH2)6-(CF2)-(CH2)3-, -(CH2)6-(CF2)-(CH2)4-, -(CH2)6-(CF2)-(CH2)5-,
-(CFH)-(CH2)-, -(CH2)-(CFH)-, -(CH2)-(CFH)-(CH2)-, -(CH2)-(CFH)-(CH2)2-,-(CH2)-(CFH)-(CH2)3-, -(CH2)-(CFH)-(CH2)4-, -(CH2)-(CFH)-(CH2)5-, -(CH2)-(CFH)-(CH2)6-, -(CH2)-(CFH)-(CH2)7-, -(CH2)-(CFH)-(CH2)8-, -(CH2)-(CFH)-(CH2)9-, -(CH2)-(CFH)-(CH2)10-, -(CH2)2-(CFH)-(CH2)-, -(CH2)3-(CFH)-(CH2)-, -(CH2)4-(CFH)-(CH2)-, -(CH2)5-(CFH)-(CH2)-, -(CH2)6-(CFH)-(CH2)-,-(CH2)7-(CFH)-(CH2)-, -(CH2)8-(CFH)-(CH2)-, -(CH2)9-(CFH)-(CH2)-, -(CH2)10-(CFH)-(CH2)-, -(CH2)2-(CFH)-(CH2)2-, -(CH2)3-(CFH)-(CH2)3-, -(CH2)4-(CFH)-(CH2)4-, -(CH2)5-(CFH)-(CH2)5-, -(CH2)2-(CFH)-(CH2)-, -(CH2)2-(CFH)-(CH2)3-, -(CH2)2-(CFH)-(CH2)4-, -(CH2)2-(CFH)-(CH2)5-, -(CH2)2-(CFH)-(CH2)6-, -(CH2)2-(CFH)-(CH2)7-, -(CH2)2-(CFH)-(CH2)8-, -(CH2)2-(CFH)-(CH2)9-, -(CH2)3-(CFH)-(CH2)-, -(CH2)3-(CFH)-(CH2)2-, -(CH2)3-(CFH)-(CH2)4-, -(CH2)3-(CFH)-(CH2)5-, -(CH2)3-(CFH)-(CH2)6-, -(CH2)3-(CFH)-(CH2)7-, -(CH2)3-(CFH)-(CH2)8-, -(CH2)4-(CFH)-(CH2)-, -(CH2)4-(CFH)-(CH2)2-, -(CH2)4-(CFH)-(CH2)3-, -(CH2)4-(CFH)-(CH2)5-, -(CH2)4-(CFH)-(CH2)6-, -(CH2)4-(CFH)-(CH2)7-, -(CH2)5-(CFH)-(CH2)-, -(CH2)5-(CFH)-(CH2)2-, -(CH2)5-(CFH)-(CH2)3-, -(CH2)5-(CFH)-(CH2)4-, -(CH2)5-(CFH)-(CH2)6-, -(CH2)6-(CFH)-(CH2)-, -(CH2)6-(CFH)-(CH2)2-, -(CH2)6-(CFH)-(CH2)3-, -(CH2)6-(CFH)-(CH2)4-, -(CH2)6-(CFH)-(CH2)5-, -(CF2)2-(CH2)-, -(CH2)-(CF2)2-, -(CH2)-(CF2)2-(CH2)-, -(CH2)-(CF2)2-(CH2)2-,-(CH2)-(CF2)2-(CH2)3-, -(CH2)-(CF2)2-(CH2)4-, -(CH2)-(CF2)2-(CH2)5-, -(CH2)-(CF2)2-(CH2)6-, -(CH2)-(CF2)2-(CH2)7-, -(CH2)-(CF2)2-(CH2)8-, -(CH2)-(CF2)2-(CH2)9-, -(CH2)2-(CF2)2-(CH2)-, -(CH2)3-(CF2)2-(CH2)-, -(CH2)4-(CF2)2-(CH2)-, -(CH2)5-(CF2)2-(CH2)-, -(CH2)6-(CF2)2-(CH2)-, -(CH2)7-(CF2)2-(CH2)-, -(CH2)8-(CF2)2-(CH2)-, -(CH2)9-(CF2)2-(CH2)-, -(CH2)2-(CF2)2-(CH2)2-, -(CH2)3-(CF2)2-(CH2)3-, -(CH2)4-(CF2)2-(CH2)4-, -(CH2)5-(CF2)2-(CH2)5-, -(CH2)2-(CF2)2-(CH2)-,-(CH2)2-(CF2)2-(CH2)3-, -(CH2)2-(CF2)2-(CH2)4-, -(CH2)2-(CF2)2-(CH2)5-, -(CH2)2-(CF2)2-(CH2)6-, -(CH2)2-(CF2)2-(CH2)7-, -(CH2)2-(CF2)2-(CH2)8-,-(CH2)3-(CF2)2-(CH2)-, -(CH2)3-(CF2)2-(CH2)2-, -(CH2)3-(CF2)2-(CH2)4-,-(CH2)3-(CF2)2-(CH2)5-, -(CH2)3-(CF2)2-(CH2)6-, -(CH2)3-(CF2)2-(CH2)7-,-(CH2)4-(CF2)2-(CH2)-, -(CH2)4-(CF2)2-(CH2)2-, -(CH2)4-(CF2)2-(CH2)3-,-(CH2)4-(CF2)2-(CH2)5-, -(CH2)4-(CF2)2-(CH2)6-, -(CH2)5-(CF2)2-(CH2)-,-(CH2)5-(CF2)2-(CH2)2-, -(CH2)5-(CF2)2-(CH2)3-, -(CH2)5-(CF2)2-(CH2)4-,-(CH2)6-(CF2)2-(CH2)-, -(CH2)6-(CF2)2-(CH2)2-, -(CH2)6-(CF2)2-(CH2)3-,-(CH2)6-(CF2)2-(CH2)4-,
-(CFH)2-(CH2)-, -(CH2)-(CFH)2-, -(CH2)-(CFH)2-(CH2)-, -(CH2)-(CFH)2-(CH2)2-, -(CH2)-(CFH)2-(CH2)3-, -(CH2)-(CFH)2-(CH2)4-, -(CH2)-(CFH)2-(CH2)5-, -(CH2)-(CFH)2-(CH2)6-, -(CH2)-(CFH)2-(CH2)7-, -(CH2)-(CFH)2-(CH2)8-, -(CH2)-(CFH)2-(CH2)9-, -(CH2)2-(CFH)2-(CH2)-, -(CH2)3-(CFH)2-(CH2)-, -(CH2)4-(CFH)2-(CH2)-, -(CH2)5-(CFH)2-(CH2)-, -(CH2)6-(CFH)2-(CH2)-, -(CH2)7-(CFH)2-(CH2)-, -(CH2)8-(CFH)2-(CH2)-, -(CH2)9-(CFH)2-(CH2)-, -(CH2)2-(CFH)2-(CH2)2-, -(CH2)3-(CFH)2-(CH2)3-, -(CH2)4-(CFH)2-(CH2)4-, -(CH2)5-(CFH)2-(CH2)5-, -(CH2)2-(CFH)2-(CH2)-,-(CH2)2-(CFH)2-(CH2)3-, -(CH2)2-(CFH)2-(CH2)4-, -(CH2)2-(CFH)2-(CH2)5-, -(CH2)2-(CFH)2-(CH2)6-, -(CH2)2-(CFH)2-(CH2)7-, -(CH2)2-(CFH)2-(CH2)8-, -(CH2)3-(CFH)2-(CH2)-, -(CH2)3-(CFH)2-(CH2)2-, -(CH2)3-(CFH)2-(CH2)4-, -(CH2)3-(CFH)2-(CH2)5-, -(CH2)3-(CFH)2-(CH2)6-, -(CH2)3-(CFH)2-(CH2)7-, -(CH2)4-(CFH)2-(CH2)-, -(CH2)4-(CFH)2-(CH2)2-, -(CH2)4-(CFH)2-(CH2)3-, -(CH2)4-(CFH)2-(CH2)5-, -(CH2)4-(CFH)2-(CH2)6-, -(CH2)5-(CFH)2-(CH2)-, -(CH2)5-(CFH)2-(CH2)2-, -(CH2)5-(CFH)2-(CH2)3-, -(CH2)5-(CFH)2-(CH2)4-, -(CH2)6-(CFH)2-(CH2)-, -(CH2)6-(CFH)2-(CH2)2-, -(CH2)6-(CFH)2-(CH2)3-, -(CH2)6-(CFH)2-(CH2)4-,
-(CF2)3-(CH2)-, -(CH2)-(CF2)3-, -(CH2)-(CF2)3-(CH2)-, -(CH2)-(CF2)3-(CH2)2-,-(CH2)-(CF2)3-(CH2)3-, -(CH2)-(CF2)3-(CH2)4-, -(CH2)-(CF2)3-(CH2)5-, -(CH2)-(CF2)3-(CH2)6-, -(CH2)-(CF2)3-(CH2)7-, -(CH2)-(CF2)3-(CH2)8-, -(CH2)2-(CF2)3-(CH2)-, -(CH2)3-(CF2)3-(CH2)-, -(CH2)4-(CF2)3-(CH2)-, -(CH2)5-(CF2)3-(CH2)-,-(CH2)6-(CF2)3-(CH2)-, -(CH2)7-(CF2)3-(CH2)-, -(CH2)8-(CF2)3-(CH2)-, -(CH2)2-(CF2)3-(CH2)2-, -(CH2)3-(CF2)3-(CH2)3-, -(CH2)4-(CF2)3-(CH2)4-, -(CH2)2-(CF2)3-(CH2)-,-(CH2)2-(CF2)3-(CH2)3-,-(CH2)2-(CF2)3-(CH2)4-,-(CH2)2-(CF2)3-(CH2)5-, -(CH2)2-(CF2)3-(CH2)6-, -(CH2)2-(CF2)3-(CH2)7-, -(CH2)3-(CF2)3-(CH2)-, -(CH2)3-(CF2)3-(CH2)2-, -(CH2)3-(CF2)3-(CH2)4-, -(CH2)3-(CF2)3-(CH2)5-, -(CH2)3-(CF2)3-(CH2)6-, -(CH2)4-(CF2)3-(CH2)-, -(CH2)4-(CF2)3-(CH2)2-, -(CH2)4-(CF2)3-(CH2)3-, -(CH2)4-(CF2)3-(CH2)5-, -(CH2)5-(CF2)3-(CH2)-, -(CH2)5-(CF2)3-(CH2)2-, -(CH2)5-(CF2)3-(CH2)3-, -(CH2)5-(CF2)3-(CH2)4-, (CH2)6-(CF2)3-(CH2)-, -(CH2)6-(CF2)3-(CH2)2-, -(CH2)6-(CF2)3-(CH2)3-,
-(CF2)4-(CH2)-, -(CH2)-(CF2)4-, -(CH2)-(CF2)4-(CH2)-, -(CH2)-(CF2)4-(CH2)2-,-(CH2)-(CF2)4-(CH2)3-, -(CH2)-(CF2)4-(CH2)4-, -(CH2)-(CF2)4-(CH2)5-, -(CH2)-(CF2)4-(CH2)6-, -(CH2)-(CF2)4-(CH2)7-, -(CH2)-(CF2)4-(CH2)8-, -(CH2)-(CF2)4-(CH2)9-, -(CH2)-(CF2)4-(CH2)10-, -(CH2)2-(CF2)4-(CH2)-, -(CH2)3-(CF2)4-(CH2)-, -(CH2)4-(CF2)4-(CH2)-, -(CH2)5-(CF2)4-(CH2)-, -(CH2)6-(CF2)4-(CH2)-,-(CH2)7-(CF2)4-(CH2)-, -(CH2)2-(CF2)4-(CH2)2-, -(CH2)3-(CF2)4-(CH2)3-,-(CH2)4-(CF2)4-(CH2)4-, -(CH2)5-(CF2)4-(CH2)5-, -(CH2)2-(CF2)4-(CH2)3-,-(CH2)2-(CF2)4-(CH2)4-, -(CH2)2-(CF2)4-(CH2)5-, -(CH2)2-(CF2)4-(CH2)6-,-(CH2)3-(CF2)4-(CH2)2-, -(CH2)3-(CF2)4-(CH2)4-, -(CH2)4-(CF2)4-(CH2)2-,-(CH2)4-(CF2)4-(CH2)3-, -(CH2)5-(CF2)4-(CH2)2-, -(CH2)5-(CF2)4-(CH2)3-,-(CH2)6-(CF2)4-(CH2)2-,
-(CF2)5-(CH2)-, -(CH2)-(CF2)5-, -(CH2)-(CF2)5-(CH2)-, -(CH2)-(CF2)5-(CH2)2-,-(CH2)-(CF2)5-(CH2)3-, -(CH2)-(CF2)5-(CH2)4-, -(CH2)-(CF2)5-(CH2)5-, -(CH2)-(CF2)5-(CH2)6-, -(CH2)2-(CF2)5-(CH2)-, -(CH2)3-(CF2)5-(CH2)-, -(CH2)4-(CF2)5-(CH2)-, -(CH2)5-(CF2)5-(CH2)-, -(CH2)6-(CF2)5-(CH2)-, -(CH2)2-(CF2)5-(CH2)2-, -(CH2)3-(CF2)5-(CH2)3-, -(CH2)4-(CF2)5-(CH2)4-, -(CH2)2-(CF2)5-(CH2)3-,-(CH2)2-(CF2)5-(CH2)4-, -(CH2)2-(CF2)5-(CH2)5-, -(CH2)2-(CF2)5-(CH2)6-,-(CH2)3-(CF2)5-(CH2)2-, -(CH2)3-(CF2)5-(CH2)4-, -(CH2)4-(CF2)5-(CH2)2-,-(CH2)4-(CF2)5-(CH2)3-, -(CH2)5-(CF2)5-(CH2)2-,
-(CHCF3)-(CH2)-, -(CH2)-(CHCF3)-, -(CH2)-(CHCF3)-(CH2)-, -(CH2)-(CHCF3)-(CH2)2-, -(CH2)-(CHCF3)-(CH2)3-, -(CH2)-(CHCF3)-(CH2)4-, -(CH2)-(CHCF3)-(CH2)5-, -(CH2)-(CHCF3)-(CH2)6-, -(CH2)-(CHCF3)-(CH2)7-, -(CH2)-(CHCF3)-(CH2)8-, -(CH2)-(CHCF3)-(CH2)9-, -(CH2)-(CHCF3)-(CH2)10-,-(CH2)2-(CHCF3)-(CH2)-, -(CH2)3-(CHCF3)-(CH2)-, -(CH2)4-(CHCF3)-(CH2)-,-(CH2)5-(CHCF3)-(CH2)-, -(CH2)6-(CHCF3)-(CH2)-, -(CH2)7-(CHCF3)-(CH2)-,-(CH2)8-(CHCF3)-(CH2)-, -(CH2)9-(CHCF3)-(CH2)-, -(CH2)io-(CHCF3)-(CH2)-,-(CH2)2-(CHCF3)-(CH2)2-, -(CH2)3-(CHCF3)-(CH2)3-, -(CH2)4-(CHCF3)-(CH2)4-, -(CH2)5-(CHCF3)-(CH2)5-, -(CH2)2-(CHCF3)-(CH2)3-, -(CH2)2-(CHCF3)-(CH2)4-, -(CH2)2-(CHCF3)-(CH2)5-, -(CH2)2-(CHCF3)-(CH2)6-, -(CH2)2-(CHCF3)-(CH2)7-, -(CH2)2-(CHCF3)-(CH2)8-, -(CH2)2-(CHCF3)-(CH2)9-,-(CH2)3-(CHCF3)-(CH2)2-, -(CH2)3-(CHCF3)-(CH2)4-, -(CH2)3-(CHCF3)-(CH2)5-, -(CH2)3-(CHCF3)-(CH2)6-, -(CH2)3-(CHCF3)-(CH2)7-, -(CH2)3-(CHCF3)-(CH2)8-, -(CH2)4-(CHCF3)-(CH2)2-, -(CH2)4-(CHCF3)-(CH2)3-, -(CH2)4-(CHCF3)-(CH2)5-, -(CH2)4-(CHCF3)-(CH2)6-, -(CH2)4-(CHCF3)-(CH2)7-,-(CH2)5-(CHCF3)-(CH2)2-, -(CH2)5-(CHCF3)-(CH2)3-, -(CH2)5-(CHCF3)-(CH2)4-, -(CH2)5-(CHCF3)-(CH2)6-, -(CH2)6-(CHCF3)-(CH2)2-, -(CH2)6-(CHCF3)-(CH2)3-, -(CH2)6-(CHCF3)-(CH2)4-, -(CH2)6-(CHCF3)-(CH2)5-, -(CHCF3)2-(CH2)-, -(CH2)-(CHCF3)2-, -(CH2)-(CHCF3)2-(CH2)-, -(CH2)-(CHCF3)2-(CH2)2-, -(CH2)-(CHCF3)2-(CH2)3-, -(CH2)-(CHCF3)2-(CH2)4-,-(CH2)-(CHCF3)2-(CH2)5-, -(CH2)-(CHCF3)2-(CH2)6-, -(CH2)-(CHCF3)2-(CH2)7-, -(CH2)-(CHCF3)2-(CH2)8-, -(CH2)-(CHCF3)2-(CH2)9-, -(CH2)2-(CHCF3)2-(CH2)-, -(CH2)3-(CHCF3)2-(CH2)-, -(CH2)4-(CHCF3)2-(CH2)-, -(CH2)5-(CHCF3)2-(CH2)-, -(CH2)6-(CHCF3)2-(CH2)-, -(CH2)7-(CHCF3)2-(CH2)-,-(CH2)8-(CHCF3)2-(CH2)-, -(CH2)9-(CHCF3)2-(CH2)-, -(CH2)2-(CHCF3)2-(CH2)2-, -(CH2)3-(CHCF3)2-(CH2)3-, -(CH2)4-(CHCF3)2-(CH2)4-, -(CH2)5-(CHCF3)2-(CH2)5-, -(CH2)2-(CHCF3)2-(CH2)3-, -(CH2)2-(CHCF3)2-(CH2)4-,-(CH2)2-(CHCF3)2-(CH2)5-, -(CH2)2-(CHCF3)2-(CH2)6-, -(CH2)2-(CHCF3)2-(CH2)7-, -(CH2)2-(CHCF3)2-(CH2)8-, -(CH2)3-(CHCF3)2-(CH2)2-, -(CH2)3-(CHCF3)2-(CH2)4-, -(CH2)3-(CHCF3)2-(CH2)5-, -(CH2)3-(CHCF3)2-(CH2)6-,-(CH2)3-(CHCF3)2-(CH2)7-, -(CH2)4-(CHCF3)2-(CH2)2-, -(CH2)4-(CHCF3)2-(CH2)3-, -(CH2)4-(CHCF3)2-(CH2)5-, -(CH2)4-(CHCF3)2-(CH2)6-, -(CH2)5-(CHCF3)2-(CH2)2-, -(CH2)5-(CHCF3)2-(CH2)3-, -(CH2)5-(CHCF3)2-(CH2)4-,-(CH2)6-(CHCF3)2-(CH2)2-, -(CH2)6-(CHCF3)2-(CH2)3-, -(CH2)6-(CHCF3)2-(CH2)4-,
-(CHCF3)3-(CH2)-, -(CH2)-(CHCF3)3-, -(CH2)-(CHCF3)3-(CH2)-, -(CH2)-(CHCF3)3-(CH2)2-, -(CH2)-(CHCF3)3-(CH2)3-, -(CH2)-(CHCF3)3-(CH2)4-,-(CH2)-(CHCF3)3-(CH2)5-, -(CH2)-(CHCF3)3-(CH2)6-, -(CH2)-(CHCF3)3-(CH2)7-, -(CH2)-(CHCF3)3-(CH2)8-, -(CH2)2-(CHCF3)3-(CH2)-, -(CH2)3-(CHCF3)3-(CH2)-, -(CH2)4-(CHCF3)3-(CH2)-, -(CH2)5-(CHCF3)3-(CH2)-, -(CH2)6-(CHCF3)3-(CH2)-, -(CH2)7-(CHCF3)3-(CH2)-, -(CH2)8-(CHCF3)3-(CH2)-,-(CH2)2-(CHCF3)3-(CH2)2-, -(CH2)3-(CHCF3)3-(CH2)3-, -(CH2)4-(CHCF3)3-(CH2)4-, -(CH2)2-(CHCF3)3-(CH2)3-, -(CH2)2-(CHCF3)3-(CH2)4-, -(CH2)2-(CHCF3)3-(CH2)5-, -(CH2)2-(CHCF3)3-(CH2)6-, -(CH2)2-(CHCF3)3-(CH2)7-,-(CH2)3-(CHCF3)3-(CH2)2-, -(CH2)3-(CHCF3)3-(CH2)4-, -(CH2)3-(CHCF3)3-(CH2)5-, -(CH2)3-(CHCF3)3-(CH2)6-, -(CH2)4-(CHCF3)3-(CH2)2-, -(CH2)4-(CHCF3)3-(CH2)3-, -(CH2)4-(CHCF3)3-(CH2)5-, -(CH2)5-(CHCF3)3-(CH2)2-,-(CH2)5-(CHCF3)3-(CH2)3-, -(CH2)5-(CHCF3)3-(CH2)4-, -(CH2)6-(CHCF3)3-(CH2)2-, -(CH2)6-(CHCF3)3-(CH2)3-,
-(CHCF3)4-(CH2)-, -(CH2)-(CHCF3)4-, -(CH2)-(CHCF3)4-(CH2)-, -(CH2)-(CHCF3)4-(CH2)2-, -(CH2)-(CHCF3)4-(CH2)3-, -(CH2)-(CHCF3)4-(CH2)4-,-(CH2)-(CHCF3)4-(CH2)5-, -(CH2)-(CHCF3)4-(CH2)6-, -(CH2)-(CHCF3)4-(CH2)7-, -(CH2)-(CHCF3)4-(CH2)8-, -(CH2)-(CHCF3)4-(CH2)9-, -(CH2)-(CHCF3)4-(CH2)10-, -(CH2)2-(CHCF3)4-(CH2)-, -(CH2)3-(CHCF3)4-(CH2)-, -(CH2)4-(CHCF3)4-(CH2)-, -(CH2)5-(CHCF3)4-(CH2)-, -(CH2)6-(CHCF3)4-(CH2)-,-(CH2)7-(CHCF3)4-(CH2)-, -(CH2)2-(CHCF3)4-(CH2)2-, -(CH2)3-(CHCF3)4-(CH2)3-, -(CH2)4-(CHCF3)4-(CH2)4-, -(CH2)5-(CHCF3)4-(CH2)5-, -(CH2)2-(CHCF3)4-(CH2)3-, -(CH2)2-(CHCF3)4-(CH2)4-, -(CH2)2-(CHCF3)4-(CH2)5-,-(CH2)2-(CHCF3)4-(CH2)6-, -(CH2)3-(CHCF3)4-(CH2)2-, -(CH2)3-(CHCF3)4-(CH2)4-, -(CH2)4-(CHCF3)4-(CH2)2-, -(CH2)4-(CHCF3)4-(CH2)3-, -(CH2)5-(CHCF3)4-(CH2)2-, -(CH2)5-(CHCF3)4-(CH2)3-, -(CH2)6-(CHCF3)4-(CH2)2-,
-(CHCF3)5-(CH2)-, -(CH2)-(CHCF3)5-, -(CH2)-(CHCF3)5-(CH2)-, -(CH2)-(CHCF3)5-(CH2)2-, -(CH2)-(CHCF3)5-(CH2)3-, -(CH2)-(CHCF3)5-(CH2)4-,-(CH2)-(CHCF3)5-(CH2)5-, -(CH2)-(CHCF3)5-(CH2)6-, -(CH2)2-(CHCF3)5-(CH2)-, -(CH2)3-(CHCF3)5-(CH2)-, -(CH2)4-(CHCF3)5-(CH2)-, -(CH2)5-(CHCF3)5-(CH2)-, -(CH2)6-(CHCF3)5-(CH2)-, -(CH2)2-(CHCF3)5-(CH2)2-, -(CH2)3-(CHCF3)5-(CH2)3-, -(CH2)4-(CHCF3)5-(CH2)4-, -(CH2)2-(CHCF3)5-(CH2)3-,-(CH2)2-(CHCF3)5-(CH2)4-, -(CH2)2-(CHCF3)5-(CH2)5-, -(CH2)2-(CHCF3)5-(CH2)6-, -(CH2)3-(CHCF3)5-(CH2)2-, -(CH2)3-(CHCF3)5-(CH2)4-, -(CH2)4-(CHCF3)5-(CH2)2-, -(CH2)4-(CHCF3)5-(CH2)3-, -(CH2)5-(CHCF3)5-(CH2)2-, -[C(CH3)CF3]-(CH2)-, -(CH2)-[C(CH3)CF3]-, -(CH2)-[C(CH3)CF3]-(CH2)-,-(CH2)-[C(CH3)CF3]-(CH2)2-, -(CH2)-[C(CH3)CF3]-(CH2)3-, -(CH2)-[C(CH3)CF3]-(CH2)4-, -(CH2)-[C(CH3)CF3]-(CH2)5-, -(CH2)-[C(CH3)CF3]-(CH2)6-, -(CH2)-[C(CH3)CF3]-(CH2)7-, -(CH2)-[C(CH3)CF3]-(CH2)8-, -(CH2)-[C(CH3)CF3]-(CH2)9-, -(CH2)-[C(CH3)CF3]-(CH2)10-, -(CH2)2-[C(CH3)CF3]-(CH2)-, -(CH2)3-[C(CH3)CF3]-(CH2)-, -(CH2)4-[C(CH3)CF3]-(CH2)-, -(CH2)5-[C(CH3)CF3]-(CH2)-, -(CH2)6-[C(CH3)CF3]-(CH2)-, -(CH2)7-[C(CH3)CF3]-(CH2)-, -(CH2)8-[C(CH3)CF3]-(CH2)-, -(CH2)9-[C(CH3)CF3]-(CH2)-, -(CH2)10-[C(CH3)CF3]-(CH2)-, -(CH2)2-[C(CH3)CF3]-(CH2)2-, -(CH2)3-[C(CH3)CF3]-(CH2)3-, -(CH2)4-[C(CH3)CF3]-(CH2)4-, -(CH2)5-[C(CH3)CF3]-(CH2)5-, -(CH2)2-[C(CH3)CF3]-(CH2)3-, -(CH2)2-[C(CH3)CF3]-(CH2)4-, -(CH2)2-[C(CH3)CF3]-(CH2)5-, -(CH2)2-[C(CH3)CF3]-(CH2)6-, -(CH2)2-[C(CH3)CF3]-(CH2)7-, -(CH2)2-[C(CH3)CF3]-(CH2)8-, -(CH2)2-[C(CH3)CF3]-(CH2)9-, -(CH2)3-[C(CH3)CF3]-(CH2)2-, -(CH2)3-[C(CH3)CF3]-(CH2)4-, -(CH2)3-[C(CH3)CF3]-(CH2)5-, -(CH2)3-[C(CH3)CF3]-(CH2)6-, -(CH2)3-[C(CH3)CF3]-(CH2)7-, -(CH2)3-[C(CH3)CF3]-(CH2)8-, -(CH2)4-[C(CH3)CF3]-(CH2)2-, -(CH2)4-[C(CH3)CF3]-(CH2)3-, -(CH2)4-[C(CH3)CF3]-(CH2)5-, -(CH2)4-[C(CH3)CF3]-(CH2)6-, -(CH2)4-[C(CH3)CF3]-(CH2)7-, -(CH2)5-[C(CH3)CF3]-(CH2)2-, -(CH2)5-[C(CH3)CF3]-(CH2)3-, -(CH2)5-[C(CH3)CF3]-(CH2)4-, -(CH2)5-[C(CH3)CF3]-(CH2)6-, -(CH2)6-[C(CH3)CF3]-(CH2)2-, -(CH2)6-[C(CH3)CF3]-(CH2)3-, -(CH2)6-[C(CH3)CF3]-(CH2)4-, -(CH2)6-[C(CH3)CF3]-(CH2)5-,
-[C(CH3)CF3]2-(CH2)-, -(CH2)-[C(CH3)CF3]2-, -(CH2)-[C(CH3)CF3]2-(CH2)-,-(CH2)-[C(CH3)CF3]2-(CH2)2-, -(CH2)-[C(CH3)CF3]2-(CH2)3-, -(CH2)-[C(CH3)CF3]2-(CH2)4-, -(CH2)-[C(CH3)CF3]2-(CH2)5-, -(CH2)-[C(CH3)CF3]2-(CH2)6-, -(CH2)-[C(CH3)CF3]2-(CH2)7-, -(CH2)-[C(CH3)CF3]2-(CH2)8-, -(CH2)-[C(CH3)CF3]2-(CH2)9-, -(CH2)2-[C(CH3)CF3]2-(CH2)-, -(CH2)3-[C(CH3)CF3]2-(CH2)-, -(CH2)4-[C(CH3)CF3]2-(CH2)-, -(CH2)5-[C(CH3)CF3]2-(CH2)-, -(CH2)6-[C(CH3)CF3]2-(CH2)-, -(CH2)7-[C(CH3)CF3]2-(CH2)-, -(CH2)8-[C(CH3)CF3]2-(CH2)-, -(CH2)9-[C(CH3)CF3]2-(CH2)-, -(CH2)2-[C(CH3)CF3]2-(CH2)2-, -(CH2)3-[C(CH3)CF3]2-(CH2)3-,-(CH2)4-[C(CH3)CF3]2-(CH2)4-,-(CH2)5-[C(CH3)CF3]2-(CH2)5-, -(CH2)2-[C(CH3)CF3]2-(CH2)3-, -(CH2)2-[C(CH3)CF3]2-(CH2)4-,-(CH2)2-[C(CH3)CF3]2-(CH2)5-, -(CH2)2-[C(CH3)CF3]2-(CH2)6-, -(CH2)2-[C(CH3)CF3]2-(CH2)7-, -(CH2)2-[C(CH3)CF3]2-(CH2)8-, -(CH2)3-[C(CH3)CF3]2-(CH2)2-, -(CH2)3-[C(CH3)CF3]2-(CH2)4-, -(CH2)3-[C(CH3)CF3]2-(CH2)5-,-(CH2)3-[C(CH3)CF3]2-(CH2)6-, -(CH2)3-[C(CH3)CF3]2-(CH2)7-, -(CH2)4-[C(CH3)CF3]2-(CH2)2-, -(CH2)4-[C(CH3)CF3]2-(CH2)3-, -(CH2)4-[C(CH3)CF3]2-(CH2)5-, -(CH2)4-[C(CH3)CF3]2-(CH2)6-, -(CH2)5-[C(CH3)CF3]2-(CH2)2-,-(CH2)5-[C(CH3)CF3]2-(CH2)3-, -(CH2)5-[C(CH3)CF3]2-(CH2)4-, -(CH2)6-[C(CH3)CF3]2-(CH2)2-, -(CH2)6-[C(CH3)CF3]2-(CH2)3-, -(CH2)6-[C(CH3)CF3]2-(CH2)4-,
-[C(CH3)CF3]3-(CH2)-, -(CH2)-[C(CH3)CF3]3-, -(CH2)-[C(CH3)CF3]3-(CH2)-,-(CH2)-[C(CH3)CF3]3-(CH2)2-, -(CH2)-[C(CH3)CF3]3-(CH2)3-, -(CH2)-[C(CH3)CF3]3-(CH2)4-, -(CH2)-[C(CH3)CF3]3-(CH2)5-, -(CH2)-[C(CH3)CF3]3-(CH2)6-, -(CH2)-[C(CH3)CF3]3-(CH2)7-, -(CH2)-[C(CH3)CF3]3-(CH2)8-, -(CH2)2-[C(CH3)CF3]3-(CH2)-, -(CH2)3-[C(CH3)CF3]3-(CH2)-, -(CH2)4-[C(CH3)CF3]3-(CH2)-, -(CH2)5-[C(CH3)CF3]3-(CH2)-, -(CH2)6-[C(CH3)CF3]3-(CH2)-, -(CH2)7-[C(CH3)CF3]3-(CH2)-, -(CH2)8-[C(CH3)CF3]3-(CH2)-, -(CH2)2-[C(CH3)CF3]3-(CH2)2-, -(CH2)3-[C(CH3)CF3]3-(CH2)3-, -(CH2)4-[C(CH3)CF3]3-(CH2)4-, - (CH2)2-[C(CH3)CF3]3-(CH2)3-, -(CH2)2-[C(CH3)CF3]3-(CH2)4-, -(CH2)2-[C(CH3)CF3]3-(CH2)5-, -(CH2)2-[C(CH3)CF3]3-(CH2)6-, -(CH2)2-[C(CH3)CF3]3-(CH2)7-, -(CH2)3-[C(CH3)CF3]3-(CH2)2-, -(CH2)3-[C(CH3)CF3]3-(CH2)4-, - (CH2)3-[C(CH3)CF3]3-(CH2)5-, -(CH2)3-[C(CH3)CF3]3-(CH2)6-, -(CH2)4-[C(CH3)CF3]3-(CH2)2-, -(CH2)4-[C(CH3)CF3]3-(CH2)3-, -(CH2)4-[C(CH3)CF3]3-(CH2)5-, -(CH2)5-[C(CH3)CF3]3-(CH2)2-, -(CH2)5-[C(CH3)CF3]3-(CH2)3-, - (CH2)5-[C(CH3)CF3]3-(CH2)4-, -(CH2)6-[C(CH3)CF3]3-(CH2)2-, -(CH2)6-[C(CH3)CF3]3-(CH2)3-,
-[C(CH3)CF3]4-(CH2)-, -(CH2)-[C(CH3)CF3]4-, -(CH2)-[C(CH3)CF3]4-(CH2)-, - (CH2)-[C(CH3)CF3]4-(CH2)2-, -(CH2)-[C(CH3)CF3]4-(CH2)3-, -(CH2)-[C(CH3)CF3]4-(CH2)4-, -(CH2)-[C(CH3)CF3]4-(CH2)5-, -(CH2)-[C(CH3)CF3]4-(CH2)6-, -(CH2)-[C(CH3)CF3]4-(CH2)7-, -(CH2)-[C(CH3)CF3]4-(CH2)8-, -(CH2)-[C(CH3)CF3]4-(CH2)9-, -(CH2)-[C(CH3)CF3]4-(CH2)10-, -(CH2)2-[C(CH3)CF3]4-(CH2)-, -(CH2)3-[C(CH3)CF3]4-(CH2)-, -(CH2)4-[C(CH3)CF3]4-(CH2)-, -(CH2)5-[C(CH3)CF3]4-(CH2)-, -(CH2)6-[C(CH3)CF3]4-(CH2)-, -(CH2)7-[C(CH3)CF3]4-(CH2)-, -(CH2)2-[C(CH3)CF3]4-(CH2)2-, -(CH2)3-[C(CH3)CF3]4-(CH2)3-, - (CH2)4-[C(CH3)CF3]4-(CH2)4-, -(CH2)5-[C(CH3)CF3]4-(CH2)5-, -(CH2)2-[C(CH3)CF3]4-(CH2)3-, -(CH2)2-[C(CH3)CF3]4-(CH2)4-, -(CH2)2-[C(CH3)CF3]4-(CH2)5-, -(CH2)2-[C(CH3)CF3]4-(CH2)6-, -(CH2)3-[C(CH3)CF3]4-(CH2)2-, - (CH2)3-[C(CH3)CF3]4-(CH2)4-, -(CH2)4-[C(CH3)CF3]4-(CH2)2-, -(CH2)4-[C(CH3)CF3]4-(CH2)3-, -(CH2)5-[C(CH3)CF3]4-(CH2)2-, -(CH2)5-[C(CH3)CF3]4-(CH2)3-, -(CH2)6-[C(CH3)CF3]4-(CH2)2-,
-[C(CH3)CF3]5-(CH2)-, -(CH2)-[C(CH3)CF3]5-, -(CH2)-[C(CH3)CF3]5-(CH2)-, - (CH2)-[C(CH3)CF3]5-(CH2)2-, -(CH2)-[C(CH3)CF3]5-(CH2)3-, -(CH2)-[C(CH3)CF3]5-(CH2)4-, -(CH2)-[C(CH3)CF3]5-(CH2)5-, -(CH2)-[C(CH3)CF3]5-(CH2)6-, -(CH2)2-[C(CH3)CF3]5-(CH2)-, -(CH2)3-[C(CH3)CF3]5-(CH2)-, -(CH2)4-[C(CH3)CF3]5-(CH2)-, -(CH2)5-[C(CH3)CF3]5-(CH2)-, -(CH2)6-[C(CH3)CF3]5-(CH2)-, -(CH2)2-[C(CH3)CF3]5-(CH2)2-, -(CH2)3-[C(CH3)CF3]5-(CH2)3-, - (CH2)4-[C(CH3)CF3]5-(CH2)4-, -(CH2)2-[C(CH3)CF3]5-(CH2)3-, -(CH2)2-[C(CH3)CF3]5-(CH2)4-, -(CH2)2-[C(CH3)CF3]5-(CH2)5-, -(CH2)2-[C(CH3)CF3]5-(CH2)6-, -(CH2)3-[C(CH3)CF3]5-(CH2)2-, -(CH2)3-[C(CH3)CF3]5-(CH2)4-, - (CH2)4-[C(CH3)CF3]5-(CH2)2-, -(CH2)4-[C(CH3)CF3]5-(CH2)3-, -(CH2)5-[C(CH3)CF3]5-(CH2)2-,
-[CH(CH2CF3)]-(CH2)-, -(CH2)-[CH(CH2CF3)]-, -(CH2)-[CH(CH2CF3)]-(CH2)-, -(CH2)-[CH(CH2CF3)]-(CH2)2-, -(CH2)-[CH(CH2CF3)] -(CH2)3-, -(CH2)-[CH(CH2CF3)]-(CH2)4-, -(CH2)-[CH(CH2CF3)]-(CH2)5-, -(CH2)-[CH(CH2CF3)]-(CH2)6-, -(CH2)-[CH(CH2CF3)]-(CH2)7-, -(CH2)-[CH(CH2CF3)]-(CH2)8-, - (CH2)-[CH(CH2CF3)]-(CH2)9-, -(CH2)-[CH(CH2CF3)]-(CH2)10-, -(CH2)2-[CH(CH2CF3)]-(CH2)-, -(CH2)3-[CH(CH2CF3)]-(CH2)-, -(CH2)4-[CH(CH2CF3)]-(CH2)-, -(CH2)5-[CH(CH2CF3)]-(CH2)-, -(CH2)6-[CH(CH2CF3)]-(CH2)-, - (CH2)7-[CH(CH2CF3)]-(CH2)-, -(CH2)8-[CH(CH2CF3)]-(CH2)-, -(CH2)9-[CH(CH2CF3)]-(CH2)-, -(CH2)10-[CH(CH2CF3)]-(CH2)-, -(CH2)2-[CH(CH2CF3)]-(CH2)2-, -(CH2)3-[CH(CH2CF3)]-(CH2)3-, -(CH2)4-[CH(CH2CF3)]-(CH2)4-, -(CH2)5-[CH(CH2CF3)]-(CH2)5-, -(CH2)2-[CH(CH2CF3)]-(CH2)3-, -(CH2)2-[CH(CH2CF3)]-(CH2)4-, -(CH2)2-[CH(CH2CF3)]-(CH2)5-, -(CH2)2-[CH(CH2CF3)]-(CH2)6-, -(CH2)2-[CH(CH2CF3)]-(CH2)7-, -(CH2)2-[CH(CH2CF3)]-(CH2)8-, -(CH2)2-[CH(CH2CF3)]-(CH2)9-, -(CH2)3-[CH(CH2CF3)]-(CH2)2-, -(CH2)3-[CH(CH2CF3)]-(CH2)4-, -(CH2)3-[CH(CH2CF3)]-(CH2)5-, -(CH2)3-[CH(CH2CF3)]-(CH2)6-, -(CH2)3-[CH(CH2CF3)]-(CH2)7-, -(CH2)3-[CH(CH2CF3)]-(CH2)8-, -(CH2)4-[CH(CH2CF3)]-(CH2)2-, -(CH2)4-[CH(CH2CF3)]-(CH2)3-, -(CH2)4-[CH(CH2CF3)]-(CH2)5-, -(CH2)4-[CH(CH2CF3)]-(CH2)6-, -(CH2)4-[CH(CH2CF3)HCH2)7-, -(CH2)5-[CH(CH2CF3)]-(CH2)2-, -(CH2)5-[CH(CH2CF3)]-(CH2)3-, -(CH2)5-[CH(CH2CF3)]-(CH2)4-, -(CH2)5-[CH(CH2CF3)]-(CH2)6-, -(CH2)6-[CH(CH2CF3)]-(CH2)2-, -(CH2)6-[CH(CH2CF3)]-(CH2)3-, -(CH2)6-[CH(CH2CF3)]-(CH2)4-, -(CH2)6-[CH(CH2CF3)]-(CH2)5-, -[CH(CH2CF3)]2-(CH2)-, -(CH2)-[CH(CH2CF3)]2-, -(CH2)-[CH(CH2CF3)]2-(CH2)-, -(CH2)-[CH(CH2CF3)]2-(CH2)2-, -(CH2)-[CH(CH2CF3)]2-(CH2)3-, - (CH2)-[CH(CH2CF3)]2-(CH2)4-, -(CH2)-[CH(CH2CF3)]2-(CH2)5-, -(CH2)-[CH(CH2CF3)]2-(CH2)6-, -(CH2)-[CH(CH2CF3)]2-(CH2)7-, -(CH2)-[CH(CH2CF3)]2-(CH2)8-, -(CH2)-[CH(CH2CF3)]2-(CH2)9-, -(CH2)2-[CH(CH2CF3)]2-(CH2)-, -(CH2)3-[CH(CH2CF3)]2-(CH2)-, -(CH2)4-[CH(CH2CF3)]2-(CH2)-, -(CH2)5-[CH(CH2CF3)]2-(CH2)-, -(CH2)6-[CH(CH2CF3)]2-(CH2)-, -(CH2)7-[CH(CH2CF3)]2-(CH2)-, -(CH2)8-[CH(CH2CF3)]2-(CH2)-, -(CH2)9-[CH(CH2CF3)]2-(CH2)-, -(CH2)2-[CH(CH2CF3)]2-(CH2)2-, -(CH2)3-[CH(CH2CF3)]2-(CH2)3-, -(CH2)4-[CH(CH2CF3)]2-(CH2)4-, -(CH2)5-[CH(CH2CF3)]2-(CH2)5-, -(CH2)2-[CH(CH2CF3)]2-(CH2)3-, -(CH2)2-[CH(CH2CF3)]2-(CH2)4-, -(CH2)2-[CH(CH2CF3)]2-(CH2)5-, -(CH2)2-[CH(CH2CF3)]2-(CH2)6-, -(CH2)2-[CH(CH2CF3)]2-(CH2)7-, -(CH2)2-[CH(CH2CF3)]2-(CH2)8-, -(CH2)3-[CH(CH2CF3)]2-(CH2)2-, -(CH2)3-[CH(CH2CF3)]2-(CH2)4-, -(CH2)3-[CH(CH2CF3)]2-(CH2)5-, -(CH2)3-[CH(CH2CF3)]2-(CH2)6-, -(CH2)3-[CH(CH2CF3)]2-(CH2)7-, -(CH2)4-[CH(CH2CF3)]2-(CH2)2-, -(CH2)4-[CH(CH2CF3)]2-(CH2)3-, -(CH2)4-[CH(CH2CF3)]2-(CH2)5-, -(CH2)4-[CH(CH2CF3)]2-(CH2)6-, -(CH2)5-[CH(CH2CF3)]2-(CH2)2-, -(CH2)5-[CH(CH2CF3)]2-(CH2)3-, -(CH2)5-[CH(CH2CF3)]2-(CH2)4-, -(CH2)6-[CH(CH2CF3)]2-(CH2)2-, -(CH2)6-[CH(CH2CF3)]2-(CH2)3-, -(CH2)6-[CH(CH2CF3)]2-(CH2)4-,
-[CH(CH2CF3)]3-(CH2)-, -(CH2)-[CH(CH2CF3)]3-, -(CH2)-[CH(CH2CF3)]3-(CH2)-, -(CH2)-[CH(CH2CF3)]3-(CH2)2-, -(CH2)-[CH(CH2CF3)]3-(CH2)3-, - (CH2)-[CH(CH2CF3)]3-(CH2)4-, -(CH2)-[CH(CH2CF3)]3-(CH2)5-, -(CH2)-[CH(CH2CF3)]3-(CH2)6-, -(CH2)-[CH(CH2CF3)]3-(CH2)7-, -(CH2)-[CH(CH2CF3)]3-(CH2)8-, -(CH2)2-[CH(CH2CF3)]3-(CH2)-, -(CH2)3-[CH(CH2CF3)]3-(CH2)-, -(CH2)4-[CH(CH2CF3)]3-(CH2)-, -(CH2)5-[CH(CH2CF3)]3-(CH2)-, -(CH2)6-[CH(CH2CF3)]3-(CH2)-, -(CH2)7-[CH(CH2CF3)]3-(CH2)-, -(CH2)8-[CH(CH2CF3)]3-(CH2)-, -(CH2)2-[CH(CH2CF3)]3-(CH2)2-, -(CH2)3-[CH(CH2CF3)]3-(CH2)3-, -(CH2)4-[CH(CH2CF3)]3-(CH2)4-, -(CH2)2-[CH(CH2CF3)]3-(CH2)3-, -(CH2)2-[CH(CH2CF3)]3-(CH2)4-, -(CH2)2-[CH(CH2CF3)]3-(CH2)5-, -(CH2)2-[CH(CH2CF3)]3-(CH2)6-, -(CH2)2-[CH(CH2CF3)]3-(CH2)7-, -(CH2)3-[CH(CH2CF3)]3-(CH2)2-, -(CH2)3-[CH(CH2CF3)]3-(CH2)4-, -(CH2)3-[CH(CH2CF3)]3-(CH2)5-, -(CH2)3-[CH(CH2CF3)]3-(CH2)6-, -(CH2)4-[CH(CH2CF3)]3-(CH2)2-, -(CH2)4-[CH(CH2CF3)]3-(CH2)3-, -(CH2)4-[CH(CH2CF3)]3-(CH2)5-, -(CH2)5-[CH(CH2CF3)]3-(CH2)2-, -(CH2)5-[CH(CH2CF3)]3-(CH2)3-, -(CH2)5-[CH(CH2CF3)]3-(CH2)4-, -(CH2)6-[CH(CH2CF3)]3-(CH2)2-, -(CH2)6-[CH(CH2CF3)]3-(CH2)3-, -[CH(CH2CF3)]4-(CH2)-, -(CH2)-[CH(CH2CF3)]4-, -(CH2)-[CH(CH2CF3)]4-(CH2)-, -(CH2)-[CH(CH2CF3)]4-(CH2)2-, -(CH2)-[CH(CH2CF3)]4-(CH2)3-, - (CH2)-[CH(CH2CF3)]4-(CH2)4-, -(CH2)-[CH(CH2CF3)]4-(CH2)5-, -(CH2)-[CH(CH2CF3)]4-(CH2)6-, -(CH2)-[CH(CH2CF3)]4-(CH2)7-, -(CH2)-[CH(CH2CF3)14-(CH2)8-, -(CH2)-[CH(CH2CF3)]4-(CH2)9-, -(CH2)-[CH(CH2CF3)]4-(CH2)10-, -(CH2)2-[CH(CH2CF3)]4-(CH2)-, -(CH2)3-[CH(CH2CF3)]4-(CH2)-, -(CH2)4-[CH(CH2CF3)]4-(CH2)-, -(CH2)5-[CH(CH2CF3)]4-(CH2)-, -(CH2)6-[CH(CH2CF3)]4-(CH2)-, -(CH2)7-[CH(CH2CF3)]4-(CH2)-, -(CH2)2-[CH(CH2CF3)]4-(CH2)2-, -(CH2)3-[CH(CH2CF3)]4-(CH2)3-, -(CH2)4-[CH(CH2CF3)]4-(CH2)4-, -(CH2)5-[CH(CH2CF3)]4-(CH2)5-, -(CH2)2-[CH(CH2CF3)]4-(CH2)3-, -(CH2)2-[CH(CH2CF3)]4-(CH2)4-, -(CH2)2-[CH(CH2CF3)]4-(CH2)5-, -(CH2)2-[CH(CH2CF3)]4-(CH2)6-, -(CH2)3-[CH(CH2CF3)]4-(CH2)2-, -(CH2)3-[CH(CH2CF3)]4-(CH2)4-, -(CH2)4-[CH(CH2CF3)]4-(CH2)2-, -(CH2)4-[CH(CH2CF3)]4-(CH2)3-, -(CH2)5-[CH(CH2CF3)]4-(CH2)2-, -(CH2)5-[CH(CH2CF3)]4-(CH2)3-, -(CH2)6-[CH(CH2CF3)]4-(CH2)2-, -[CH(CH2CF3)]5-(CH2)-, -(CH2)-[CH(CH2CF3)5-, -(CH2)-[CH(CH2CF3)]5-(CH2)-, -(CH2)-[CH(CH2CF3)]5-(CH2)2-, -(CH2)-[CH(CH2CF3)]5-(CH2)3-, - (CH2)-[CH(CH2CF3)]5-(CH2)4-, -(CH2)-[CH(CH2CF3)]5-(CH2)5-, -(CH2)-[CH(CH2CF3)]5-(CH2)6-, -(CH2)2-[CH(CH2CF3)]5-(CH2)-, -(CH2)3-[CH(CH2CF3)]5-(CH2)-, -(CH2)4-[CH(CH2CF3)]5-(CH2)-, -(CH2)5-[CH(CH2CF3)]5-(CH2)-, -(CH2)6-[CH(CH2CF3)]5-(CH2)-, -(CH2)2-[CH(CH2CF3)]5-(CH2)2-, -(CH2)3-[CH(CH2CF3)]5-(CH2)3-, -(CH2)4-[CH(CH2CF3)]5-(CH2)4-, -(CH2)2-[CH(CH2CF3)]5-(CH2)3-, -(CH2)2-[CH(CH2CF3)]5-(CH2)4-, -(CH2)2-[CH(CH2CF3)]5-(CH2)5-, -(CH2)2-[CH(CH2CF3)]5-(CH2)6-, -(CH2)3-[CH(CH2CF3)]5-(CH2)2-, -(CH2)3-[CH(CH2CF3)]5-(CH2)4-, -(CH2)4-[CH(CH2CF3)]5-(CH2)2-, -(CH2)4-[CH(CH2CF3)]5-(CH2)3-, -(CH2)5-[CH(CH2CF3)]5-(CH2)2-, -[C(CH3)(CH2CF3)]-(CH2)-, -(CH2)-[C(CH3)(CH2CF3)]-, -(CH2)-[C(CH3)(CH2CF3)]-(CH2)-, -(CH2)-[C(CH3)(CH2CF3)]-(CH2)2-, -(CH2)-[C(CH3)(CH2CF3)HCH2)3-, -(CH2)-[C(CH3)(CH2CF3)]-(CH2)4-, -(CH2)-[C(CH3)(CH2CF3)]-(CH2)5-, -(CH2)-[C(CH3)(CH2CF3)]-(CH2)6-, -(CH2)-[C(CH3)(CH2CF3)]-(CH2)7-, -(CH2)-[C(CH3)(CH2CF3)]-(CH2)8-, -(CH2)-[C(CH3)(CH2CF3)]-(CH2)9-, -(CH2)-[C(CH3)(CH2CF3)]-(CH2)10-, -(CH2)2-[C(CH3)(CH2CF3)]-(CH2)-, -(CH2)3-[C(CH3)(CH2CF3)]-(CH2)-, -(CH2)4-[C(CH3)(CH2CF3)HCH2)-, -(CH2)5-[C(CH3)(CH2CF3)]-(CH2)-, -(CH2)6-[C(CH3)(CH2CF3)]-(CH2)-, -(CH2)7-[C(CH3)(CH2CF3)]-(CH2)-, -(CH2)8-[C(CH3)(CH2CF3)]-(CH2)-, -(CH2)9-[C(CH3)(CH2CF3)]-(CH2)-, -(CH2)10-[C(CH3)(CH2CF3)]-(CH2)-, -(CH2)2-[C(CH3)(CH2CF3)]-(CH2)2-, -(CH2)3-[C(CH3)(CH2CF3)]-(CH2)3-, -(CH2)4-[C(CH3)(CH2CF3)]-(CH2)4-, -(CH2)5-[C(CH3)(CH2CF3)HCH2)5-, -(CH2)2-[C(CH3)(CH2CF3)]-(CH2)3-, -(CH2)2-[C(CH3)(CH2CF3)]-(CH2)4-, -(CH2)2-[C(CH3)(CH2CF3)]-(CH2)5-, -(CH2)2-[C(CH3)(CH2CF3)]-(CH2)6-, -(CH2)2-[C(CH3)(CH2CF3)]-(CH2)7-, -(CH2)2-[C(CH3)(CH2CF3)]-(CH2)8-, -(CH2)2-[C(CH3)(CH2CF3)]-(CH2)9-, -(CH2)3-[C(CH3)(CH2CF3)]-(CH2)2-, -(CH2)3-[C(CH3)(CH2CF3)]-(CH2)4-, -(CH2)3-[C(CH3)(CH2CF3)HCH2)5-, -(CH2)3-[C(CH3)(CH2CF3)]-(CH2)6-, -(CH2)3-[C(CH3)(CH2CF3)]-(CH2)7-, -(CH2)3-[C(CH3)(CH2CF3)]-(CH2)8-, -(CH2)4-[C(CH3)(CH2CF3)]-(CH2)2-, -(CH2)4-[C(CH3)(CH2CF3)]-(CH2)3-, -(CH2)4-[C(CH3)(CH2CF3)]-(CH2)5-, -(CH2)4-[C(CH3)(CH2CF3)HCH2)6-, -(CH2)4-[C(CH3)(CH2CF3)]-(CH2)7-, -(CH2)5-[C(CH3)(CH2CF3)]-(CH2)2-, -(CH2)5-[C(CH3)(CH2CF3)]-(CH2)3-, -(CH2)5-[C(CH3)(CH2CF3)]-(CH2)4-, -(CH2)5-[C(CH3)(CH2CF3)]-(CH2)6-, -(CH2)6-[C(CH3)(CH2CF3)]-(CH2)2-, -(CH2)6-[C(CH3)(CH2CF3)]-(CH2)3-, -(CH2)6-[C(CH3)(CH2CF3)]-(CH2)4-, -(CH2)6-[C(CH3)(CH2CF3)]-(CH2)5-,
-[C(CH3)(CH2CF3)]2-(CH2)-, -(CH2)-[C(CH3)(CH2CF3)]2-, -(CH2)-[C(CH3)(CH2CF3)]2-(CH2)-, -(CH2)-[C(CH3)(CH2CF3)]2-(CH2)2-, -(CH2)-[C(CH3)(CH2CF3)]2-(CH2)3-, -(CH2)-[C(CH3)(CH2CF3)]2-(CH2)4-, -(CH2)-[C(CH3)(CH2CF3)]2-(CH2)5-, -(CH2)-[C(CH3)(CH2CF3)]2-(CH2)6-, -(CH2)-[C(CH3)(CH2CF3)]2-(CH2)7-, -(CH2)-[C(CH3)(CH2CF3)]2-(CH2)8-, -(CH2)-[C(CH3)(CH2CF3)]2-(CH2)9-, -(CH2)2-[C(CH3)(CH2CF3)]2-(CH2)-, -(CH2)3-[C(CH3)(CH2CF3)]2-(CH2)-, -(CH2)4-[C(CH3)(CH2CF3)]2-(CH2)-, -(CH2)5-[C(CH3)(CH2CF3)]2-(CH2)-, -(CH2)6-[C(CH3)(CH2CF3)]2-(CH2)-, -(CH2)7-[C(CH3)(CH2CF3)]2-(CH2)-, -(CH2)8-[C(CH3)(CH2CF3)]2-(CH2)-, -(CH2)9-[C(CH3)(CH2CF3)]2-(CH2)-, -(CH2)2-[C(CH3)(CH2CF3)]2-(CH2)2-, -(CH2)3-[C(CH3)(CH2CF3)]2-(CH2)3-, -(CH2)4-[C(CH3)(CH2CF3)]2-(CH2)4-, -(CH2)5-[C(CH3)(CH2CF3)]2-(CH2)5-, -(CH2)2-[C(CH3)(CH2CF3)]2-(CH2)3-, -(CH2)2-[C(CH3)(CH2CF3)]2-(CH2)4-, -(CH2)2-[C(CH3)(CH2CF3)]2-(CH2)5-, -(CH2)2-[C(CH3)(CH2CF3)]2-(CH2)6-, -(CH2)2-[C(CH3)(CH2CF3)]2-(CH2)7-, -(CH2)2-[C(CH3)(CH2CF3)]2-(CH2)8-, -(CH2)3-[C(CH3)(CH2CF3)]2-(CH2)2-, -(CH2)3-[C(CH3)(CH2CF3)]2-(CH2)4-, -(CH2)3-[C(CH3)(CH2CF3)]2-(CH2)5-, -(CH2)3-[C(CH3)(CH2CF3)]2-(CH2)6-, -(CH2)3-[C(CH3)(CH2CF3)]2-(CH2)7-, -(CH2)4-[C(CH3)(CH2CF3)]2-(CH2)2-, -(CH2)4-[C(CH3)(CH2CF3)]2-(CH2)3-, -(CH2)4-[C(CH3)(CH2CF3)]2-(CH2)5-, -(CH2)4-[C(CH3)(CH2CF3)]2-(CH2)6-, -(CH2)5-[C(CH3)(CH2CF3)]2-(CH2)2-, -(CH2)5-[C(CH3)(CH2CF3)]2-(CH2)3-, -(CH2)5-[C(CH3)(CH2CF3)]2-(CH2)4-, -(CH2)6-[C(CH3)(CH2CF3)]2-(CH2)2-, -(CH2)6-[C(CH3)(CH2CF3)]2-(CH2)3-, -(CH2)6-[C(CH3)(CH2CF3)]2-(CH2)4-, -[C(CH3)(CH2CF3)]3-(CH2)-, -(CH2)-[C(CH3)(CH2CF3)]3-, -(CH2)-[C(CH3)(CH2CF3)]3-(CH2)-, -(CH2)-[C(CH3)(CH2CF3)]3-(CH2)2-, -(CH2)-[C(CH3)(CH2CF3)]3-(CH2)3-, -(CH2)-[C(CH3)(CH2CF3)]3-(CH2)4-, -(CH2)-[C(CH3)(CH2CF3)]3-(CH2)5-, -(CH2)-[C(CH3)(CH2CF3)]3-(CH2)6-, -(CH2)-[C(CH3)(CH2CF3)]3-(CH2)7-, -(CH2)-[C(CH3)(CH2CF3)]3-(CH2)8-, -(CH2)2-[C(CH3)(CH2CF3)]3-(CH2)-, -(CH2)3-[C(CH3)(CH2CF3)]3-(CH2)-, -(CH2)4-[C(CH3)(CH2CF3)]3-(CH2)-, -(CH2)5-[C(CH3)(CH2CF3)]3-(CH2)-, -(CH2)6-[C(CH3)(CH2CF3)]3-(CH2)-, -(CH2)7-[C(CH3)(CH2CF3)]3-(CH2)-, -(CH2)8-[C(CH3)(CH2CF3)]3-(CH2)-, -(CH2)2-[C(CH3)(CH2CF3)]3-(CH2)2-, -(CH2)3-[C(CH3)(CH2CF3)]3-(CH2)3-, -(CH2)4-[C(CH3)(CH2CF3)]3-(CH2)4-, -(CH2)2-[C(CH3)(CH2CF3)]3-(CH2)3-, -(CH2)2-[C(CH3)(CH2CF3)]3-(CH2)4-, -(CH2)2-[C(CH3)(CH2CF3)]3-(CH2)5-, -(CH2)2-[C(CH3)(CH2CF3)]3-(CH2)6-, -(CH2)2-[C(CH3)(CH2CF3)]3-(CH2)7-, -(CH2)3-[C(CH3)(CH2CF3)]3-(CH2)2-, -(CH2)3-[C(CH3)(CH2CF3)]3-(CH2)4-, -(CH2)3-[C(CH3)(CH2CF3)]3-(CH2)5-, -(CH2)3-[C(CH3)(CH2CF3)]3-(CH2)6-, -(CH2)4-[C(CH3)(CH2CF3)]3-(CH2)2-, -(CH2)4-[C(CH3)(CH2CF3)]3-(CH2)3-, -(CH2)4-[C(CH3)(CH2CF3)]3-(CH2)5-, -(CH2)5-[C(CH3)(CH2CF3)]3-(CH2)2-, -(CH2)5-[C(CH3)(CH2CF3)]3-(CH2)3-, -(CH2)5-[C(CH3)(CH2CF3)]3-(CH2)4-, -(CH2)6-[C(CH3)(CH2CF3)]3-(CH2)2-, -(CH2)6-[C(CH3)(CH2CF3)]3-(CH2)3-,
-[C(CH3)(CH2CF3)]4-(CH2)-, -(CH2)-[C(CH3)(CH2CF3)]4-, -(CH2)-[C(CH3)(CH2CF3)]4-(CH2)-, -(CH2)-[C(CH3)(CH2CF3)]4-(CH2)2-, -(CH2)-[C(CH3)(CH2CF3)]4-(CH2)3-, -(CH2)-[C(CH3)(CH2CF3)]4-(CH2)4-, -(CH2)-[C(CH3)(CH2CF3)]4-(CH2)5-, -(CH2)-[C(CH3)(CH2CF3)]4-(CH2)6-, -(CH2)-[C(CH3)(CH2CF3)]4-(CH2)7-, -(CH2)-[C(CH3)(CH2CF3)]4-(CH2)8-, -(CH2)-[C(CH3)(CH2CF3)]4-(CH2)9-, -(CH2)-[C(CH3)(CH2CF3)14-(CH2)10-, -(CH2)2-[C(CH3)(CH2CF3)]4-(CH2)-, -(CH2)3-[C(CH3)(CH2CF3)]4-(CH2)-, -(CH2)4-[C(CH3)(CH2CF3)]4-(CH2)-, -(CH2)5-[C(CH3)(CH2CF3)]4-(CH2)-, -(CH2)6-[C(CH3)(CH2CF3)]4-(CH2)-, -(CH2)7-[C(CH3)(CH2CF3)]4-(CH2)-, -(CH2)2-[C(CH3)(CH2CF3)]4-(CH2)2-, -(CH2)3-[C(CH3)(CH2CF3)]4-(CH2)3-, -(CH2)4-[C(CH3)(CH2CF3)]4-(CH2)4-, -(CH2)5-[C(CH3)(CH2CF3)]4-(CH2)5-, -(CH2)2-[C(CH3)(CH2CF3)]4-(CH2)3-, -(CH2)2-[C(CH3)(CH2CF3)]4-(CH2)4-, -(CH2)2-[C(CH3)(CH2CF3)]4-(CH2)5-, -(CH2)2-[C(CH3)(CH2CF3)]4-(CH2)6-, -(CH2)3-[C(CH3)(CH2CF3)]4-(CH2)2-, -(CH2)3-[C(CH3)(CH2CF3)]4-(CH2)4-, -(CH2)4-[C(CH3)(CH2CF3)]4-(CH2)2-, -(CH2)4-[C(CH3)(CH2CF3)]4-(CH2)3-, -(CH2)5-[C(CH3)(CH2CF3)]4-(CH2)2-, -(CH2)5-[C(CH3)(CH2CF3)]4-(CH2)3-, -(CH2)6-[C(CH3)(CH2CF3)]4-(CH2)2-,
-[C(CH3)(CH2CF3)]5-(CH2)-, -(CH2)-[C(CH3)(CH2CF3)]5-, -(CH2)-[C(CH3)(CH2CF3)]5-(CH2)-, -(CH2)-[C(CH3)(CH2CF3)]5-(CH2)2-, -(CH2)-[C(CH3)(CH2CF3)]5-(CH2)3-, -(CH2)-[C(CH3)(CH2CF3)]5-(CH2)4-, -(CH2)-[C(CH3)(CH2CF3)]5-(CH2)5-, -(CH2)-[C(CH3)(CH2CF3)]5-(CH2)6-, -(CH2)2-[C(CH3)(CH2CF3)]5-(CH2)-, -(CH2)3-[C(CH3)(CH2CF3)]5-(CH2)-, -(CH2)4-[C(CH3)(CH2CF3)]5-(CH2)-, -(CH2)5-[C(CH3)(CH2CF3)]5-(CH2)-, -(CH2)6-[C(CH3)(CH2CF3)]5-(CH2)-, -(CH2)2-[C(CH3)(CH2CF3)]5-(CH2)2-, -(CH2)3-[C(CH3)(CH2CF3)]5-(CH2)3-, -(CH2)4-[C(CH3)(CH2CF3)]5-(CH2)4-, -(CH2)2-[C(CH3)(CH2CF3)]5-(CH2)3-, -(CH2)2-[C(CH3)(CH2CF3)]5-(CH2)4-, -(CH2)2-[C(CH3)(CH2CF3)]5-(CH2)5-, -(CH2)2-[C(CH3)(CH2CF3)]5-(CH2)6-, -(CH2)3-[C(CH3)(CH2CF3)]5-(CH2)2-, -(CH2)3-[C(CH3)(CH2CF3)]5-(CH2)4-, -(CH2)4-[C(CH3)(CH2CF3)]5-(CH2)2-, -(CH2)4-[C(CH3)(CH2CF3)]5-(CH2)3-, -(CH2)5-[C(CH3)(CH2CF3)]5-(CH2)2-,
-(CH2)-(CF2)-O-(CF2)-O-(CF2)-(CH2)-, -(CH2)2-(CF2)-O-(CF2)-O-(CF2)-(CH2)2-, -(CH2)3-(CF2)-O-(CF2)-O-(CF2)-(CH2)3-, -(CH2)4-(CF2)-O-(CF2)-O-(CF2)-(CH2)4-, -(CH2)-(CF2)-O-(CF2)-O-(CF2)-(CH2)2-, -(CH2)-(CF2)-O-(CF2)-O-(CF2)-(CH2)3-, -(CH2)-(CF2)-O-(CF2)-O-(CF2)-(CH2)4-, -(CH2)-(CF2)-O-(CF2)-O-(CF2)-(CH2)5-, -(CH2)-(CF2)-O-(CF2)-O-(CF2)-(CH2)6-, -(CH2)-(CF2)-O-(CF2)-O-(CF2)-(CH2)7-, -(CH2)2-(CF2)-O-(CF2)-O-(CF2)-(CH2)-, -(CH2)3-(CF2)-O-(CF2)-O-(CF2)-(CH2)-, -(CH2)4-(CF2)-O-(CF2)-O-(CF2)-(CH2)-, -(CH2)5-(CF2)-O-(CF2)-O-(CF2)-(CH2)-, -(CH2)6-(CF2)-O-(CF2)-O-(CF2)-(CH2)-, -(CH2)7-(CF2)-O-(CF2)-O-(CF2)-(CH2)-, -(CH2)2-(CF2)-O-(CF2)-O-(CF2)-(CH2)3-, -(CH2)2-(CF2)-O-(CF2)-O-(CF2)-(CH2)4-, -(CH2)2-(CF2)-O-(CF2)-O-(CF2)-(CH2)5-, -(CH2)2-(CF2)-O-(CF2)-O-(CF2)-(CH2)6-, -(CH2)3-(CF2)-O-(CF2)-O-(CF2)-(CH2)2-, -(CH2)4-(CF2)-O-(CF2)-O-(CF2)-(CH2)2-, -(CH2)5-(CF2)-O-(CF2)-O-(CF2)-(CH2)2-, -(CH2)6-(CF2)-O-(CF2)-O-(CF2)-(CH2)2-, -(CH2)3-(CF2)-O-(CF2)-O-(CF2)-(CH2)4-, -(CH2)4-(CF2)-O-(CF2)-O-(CF2)-(CH2)3-, -(CH2)3-(CF2)-O-(CF2)-O-(CF2)-(CH2)5-, -(CH2)5-(CF2)-O-(CF2)-O-(CF2)-(CH2)3-,
-(CH2)-(CF2)-O-(CF2)2-O-(CF2)-(CH2)-, -(CH2)2-(CF2)-O-(CF2)2-O-(CF2)-(CH2)2-, -(CH2)3-(CF2)-O-(CF2)2-O-(CF2)-(CH2)3-, -(CH2)4-(CF2)-O-(CF2)2-O-(CF2)-(CH2)4-, -(CH2)-(CF2)-O-(CF2)2-O-(CF2)-(CH2)2-, -(CH2)-(CF2)-O-(CF2)2-O-(CF2)-(CH2)3-, -(CH2)-(CF2)-O-(CF2)2-O-(CF2)-(CH2)4-, -(CH2)-(CF2)-O-(CF2)2-O-(CF2)-(CH2)5-, -(CH2)-(CF2)-O-(CF2)2-O-(CF2)-(CH2)6-, -(CH2)-(CF2)-O-(CF2)2-O-(CF2)-(CH2)7-, -(CH2)2-(CF2)-O-(CF2)2-O-(CF2)-(CH2)-, -(CH2)3-(CF2)-O-(CF2)2-O-(CF2)-(CH2)-, -(CH2)4-(CF2)-O-(CF2)2-O-(CF2)-(CH2)-, -(CH2)5-(CF2)-O-(CF2)2-O-(CF2)-(CH2)-, -(CH2)6-(CF2)-O-(CF2)2-O-(CF2)-(CH2)-, -(CH2)7-(CF2)-O-(CF2)2-O-(CF2)-(CH2)-, -(CH2)2-(CF2)-O-(CF2)2-O-(CF2)-(CH2)3-, -(CH2)2-(CF2)-O-(CF2)2-O-(CF2)-(CH2)4-, -(CH2)2-(CF2)-O-(CF2)2-O-(CF2)-(CH2)5-, -(CH2)2-(CF2)-O-(CF2)2-O-(CF2)-(CH2)6-, -(CH2)3-(CF2)-O-(CF2)2-O-(CF2)-(CH2)2-, -(CH2)4-(CF2)-O-(CF2)2-O-(CF2)-(CH2)2-, -(CH2)5-(CF2)-O-(CF2)2-O-(CF2)-(CH2)2-, -(CH2)6-(CF2)-O-(CF2)2-O-(CF2)-(CH2)2-, -(CH2)3-(CF2)-O-(CF2)2-O-(CF2)-(CH2)4-, -(CH2)4-(CF2)-O-(CF2)2-O-(CF2)-(CH2)3-, -(CH2)3-(CF2)-O-(CF2)2-O-(CF2)-(CH2)5-, -(CH2)5-(CF2)-O-(CF2)2-O-(CF2)-(CH2)3-,
-(CH2)-(CF2)2-O-(CF2)2-O-(CF2)2-(CH2)-, -(CH2)2-(CF2)2-O-(CF2)2-O-(CF2)2-(CH2)2-, -(CH2)3-(CF2)2-O-(CF2)2-O-(CF2)2-(CH2)3-, -(CH2)4-(CF2)2-O-(CF2)2-O-(CF2)2-(CH2)4-, -(CH2)-(CF2)2-O-(CF2)2-O-(CF2)2-(CH2)2-, -(CH2)-(CF2)2-O-(CF2)2-O-(CF2)2-(CH2)3-, -(CH2)-(CF2)2-O-(CF2)2-O-(CF2)2-(CH2)3-, -(CH2)-(CF2)2-O-(CF2)2-O-(CF2)2-(CH2)4-, -(CH2)-(CF2)2-O-(CF2)2-O-(CF2)2-(CH2)5-, -(CH2)-(CF2)2-O-(CF2)2-O-(CF2)2-(CH2)6-, -(CH2)-(CF2)2-O-(CF2)2-O-(CF2)2-(CH2)7-, -(CH2)2-(CF2)2-O-(CF2)2-O-(CF2)2-(CH2)-, -(CH2)3-(CF2)2-O-(CF2)2-O-(CF2)2-(CH2)-, -(CH2)4-(CF2)2-O-(CF2)2-O-(CF2)2-(CH2)-, -(CH2)5-(CF2)2-O-(CF2)2-O-(CF2)2-(CH2)-, -(CH2)6-(CF2)2-O-(CF2)2-O-(CF2)2-(CH2)-, -(CH2)7-(CF2)2-O-(CF2)2-O-(CF2)2-(CH2)-, -(CH2)2-(CF2)2-O-(CF2)2-O-(CF2)2-(CH2)3-, -(CH2)2-(CF2)2-O-(CF2)2-O-(CF2)2-(CH2)4-, -(CH2)2-(CF2)2-O-(CF2)2-O-(CF2)2-(CH2)5-, -(CH2)2-(CF2)2-O-(CF2)2-O-(CF2)2-(CH2)6-, -(CH2)3-(CF2)2-O-(CF2)2-O-(CF2)2-(CH2)2-, -(CH2)4-(CF2)2-O-(CF2)2-O-(CF2)2-(CH2)2-, -(CH2)5-(CF2)2-O-(CF2)2-O-(CF2)2-(CH2)2-, -(CH2)6-(CF2)2-O-(CF2)2-O-(CF2)2-(CH2)2-, -(CH2)3-(CF2)2-O-(CF2)2-O-(CF2)2-(CH2)4-, -(CH2)4-(CF2)2-O-(CF2)2-O-(CF2)2-(CH2)3-, -(CH2)3-(CF2)2-O-(CF2)2-O-(CF2)2-(CH2)5-, -(CH2)5-(CF2)2-O-(CF2)2-O-(CF2)2-(CH2)3-,
-(CH2)-(CF2)-O-(CF2)-O-(CF2)-O-(CF2)-(CH2)-, -(CH2)2-(CF2)-O-(CF2)-O-(CF2)-O-(CF2)-(CH2)2-, -(CH2)3-(CF2)-O-(CF2)-O-(CF2)-O-(CF2)-(CH2)3-, -(CH2)4-(CF2)-O-(CF2)-O-(CF2)-O-(CF2)-(CH2)4-, -(CH2)-(CF2)-O-(CF2)-O-(CF2)-O-(CF2)-(CH2)2-, -(CH2)-(CF2)-O-(CF2)-O-(CF2)-O-(CF2)-(CH2)3-, -(CH2)-(CF2)-O-(CF2)-O-(CF2)-O-(CF2)-(CH2)4-, -(CH2)-(CF2)-O-(CF2)-O-(CF2)-O-(CF2)-(CH2)5-, -(CH2)-(CF2)-O-(CF2)-O-(CF2)-O-(CF2)-(CH2)6-, -(CH2)-(CF2)-O-(CF2)-O-(CF2)-O-(CF2)-(CH2)7-, -(CH2)2-(CF2)-O-(CF2)-O-(CF2)-O-(CF2)-(CH2)-, -(CH2)3-(CF2)-O-(CF2)-O-(CF2)-O-(CF2)-(CH2)-, -(CH2)4-(CF2)-O-(CF2)-O-(CF2)-O-(CF2)-(CH2)-, -(CH2)5-(CF2)-O-(CF2)-O-(CF2)-O-(CF2)-(CH2)-, -(CH2)6-(CF2)-O-(CF2)-O-(CF2)-O-(CF2)-(CH2)-, -(CH2)7-(CF2)-O-(CF2)-O-(CF2)-O-(CF2)-(CH2)-, -(CH2)2-(CF2)-O-(CF2)-O-(CF2)-O-(CF2)-(CH2)3-, -(CH2)2-(CF2)-O-(CF2)-O-(CF2)-O-(CF2)-(CH2)4-, -(CH2)2-(CF2)-O-(CF2)-O-(CF2)-O-(CF2)-(CH2)5-, -(CH2)2-(CF2)-O-(CF2)-O-(CF2)-O-(CF2)-(CH2)6-, -(CH2)3-(CF2)-O-(CF2)-O-(CF2)-O-(CF2)-(CH2)2-, -(CH2)4-(CF2)-O-(CF2)-O-(CF2)-O-(CF2)-(CH2)2-, -(CH2)5-(CF2)-O-(CF2)-O-(CF2)-O-(CF2)-(CH2)2-, -(CH2)6-(CF2)-O-(CF2)-O-(CF2)-O-(CF2)-(CH2)2-, -(CH2)3-(CF2)-O-(CF2)-O-(CF2)-O-(CF2)-(CH2)4-, -(CH2)4-(CF2)-O-(CF2)-O-(CF2)-O-(CF2)-(CH2)3-, -(CH2)3-(CF2)-O-(CF2)-O-(CF2)-O-(CF2)-(CH2)5-, -(CH2)5-(CF2)-O-(CF2)-O-(CF2)-O-(CF2)-(CH2)3-,
-(CH2)-(CF2)2-O-(CF2)2-O-(CF2)2-O-(CF2)2-(CH2)-, -(CH2)2-(CF2)2-O-(CF2)2-O-(CF2)2-O-(CF2)2-(CH2)2-, -(CH2)3-(CF2)2-O-(CF2)2-O-(CF2)2-O-(CF2)2-(CH2)3-, -(CH2)4-(CF2)2-O-(CF2)2-O-(CF2)2-O-(CF2)2-(CH2)4-, -(CH2)-(CF2)2-O-(CF2)2-O-(CF2)2-O-(CF2)2-(CH2)2-, -(CH2)-(CF2)2-O-(CF2)2-O-(CF2)2-O-(CF2)2-(CH2)3-, -(CH2)-(CF2)2-O-(CF2)2-O-(CF2)2-O-(CF2)2-(CH2)4-, -(CH2)-(CF2)2-O-(CF2)2-O-(CF2)2-O-(CF2)2-(CH2)5-, -(CH2)-(CF2)2-O-(CF2)2-O-(CF2)2-O-(CF2)2-(CH2)6-, -(CH2)-(CF2)2-O-(CF2)2-O-(CF2)2-O-(CF2)2-(CH2)7-, -(CH2)2-(CF2)2-O-(CF2)2-O-(CF2)2-O-(CF2)2-(CH2)-, -(CH2)3-(CF2)2-O-(CF2)2-O-(CF2)2-O-(CF2)2-(CH2)-, -(CH2)4-(CF2)2-O-(CF2)2-O-(CF2)2-O-(CF2)2-(CH2)-, -(CH2)5-(CF2)2-O-(CF2)2-O-(CF2)2-O-(CF2)2-(CH2)-, -(CH2)6-(CF2)2-O-(CF2)2-O-(CF2)2-O-(CF2)2-(CH2)-, -(CH2)7-(CF2)2-O-(CF2)2-O-(CF2)2-O-(CF2)2-(CH2)-, -(CH2)2-(CF2)2-O-(CF2)2-O-(CF2)2-O-(CF2)2-(CH2)3-, -(CH2)2-(CF2)2-O-(CF2)2-O-(CF2)2-O-(CF2)2-(CH2)4-, -(CH2)2-(CF2)2-O-(CF2)2-O-(CF2)2-O-(CF2)2-(CH2)5-, -(CH2)2-(CF2)2-O-(CF2)2-O-(CF2)2-O-(CF2)2-(CH2)6-, -(CH2)3-(CF2)2-O-(CF2)2-O-(CF2)2-O-(CF2)2-(CH2)2-, -(CH2)4-(CF2)2-O-(CF2)2-O-(CF2)2-O-(CF2)2-(CH2)2-, -(CH2)5-(CF2)2-O-(CF2)2-O-(CF2)2-O-(CF2)2-(CH2)2-, -(CH2)6-(CF2)2-O-(CF2)2-O-(CF2)2-O-(CF2)2-(CH2)2-, -(CH2)3-(CF2)2-O-(CF2)2-O-(CF2)2-O-(CF2)2-(CH2)4-, -(CH2)4-(CF2)2-O-(CF2)2-O-(CF2)2-O-(CF2)2-(CH2)3-, -(CH2)3-(CF2)2-O-(CF2)2-O-(CF2)2-O-(CF2)2-(CH2)5-, -(CH2)5-(CF2)2-O-(CF2)2-O-(CF2)2-O-(CF2)2-(CH2)3-,





[0084] Preferred examples for -R2- are -(CH2)3-(CF2)-(CH2)3-, -(CH2)-(CF2)3-(CH2)-, -(CH2)2-(CF2)4-(CH2)2-, -(CH2)-[CH(CF3)]-(CH2)-, -(CH2)-[C(CH3)CF3]-(CH2)-, -(CH2)-[CH(CH2CF3)]-(CH2)-, -(CH2)-[C(CH3)(CH2CF3)]-(CH2)-, -(CH2)2-(CF2)-O-(CF2)-O-(CF2)-(CH2)2-, -(CH2)-(CF2)-O-(CF2)-O-(CF2)-O-(CF2)-(CH2)-,



[0085] Compounds of formula (I') with linkers -[B]- and substituents as described before or preferably described before having a polymerizable group as described before or preferably described before or below are preferred in case the substituent -R2- within the linking element Y-R2- corresponds to -(C(R)2)o-, wherein at least one R is F or a linear or branched partially or fully fluorinated alkyl group having 1 to 4 C atoms or -(C(R)2)p-X8-(C(R)2)q-(X9)s-(C(R)2)r-(X10)t-(C(R)2)u-, wherein at least one R is F or a linear or branched partially or fully fluorinated alkyl group having 1 to 4 C atoms and R, o, X8, X9, X10, s, t, p, q, r and u have a meaning as described before.

[0086] The invention therefore relates to compounds of formula (I') as described before or preferably described before wherein -R2- is -(C(R)2)o-, wherein at least one R is F or a linear or branched partially or fully fluorinated alkyl group having 1 to 4 C atoms or -(C(R)2)p-X8-(C(R)2)q-(X9)s-(C(R)2)r-(X10)t-(C(R)2)u-, wherein at least one R is F or a linear or branched partially or fully fluorinated alkyl group having 1 to 4 C atoms and all other R, and o, X8, X9, X10, s, t, p, q, r and u have a meaning as described before.

[0087] The linking element -(C(R)2)o- or -(C(R)2)p-X8-(C(R)2)q-(X9)s-(C(R)2)r-(X10)t-(C(R)2)u- as -R2- is particularly preferably selected from the group consisting of -(CH2)3-(CF2)-(CH2)3-, -(CH2)-(CF2)3-(CH2)-, -(CH2)2-(CF2)4-(CH2)2-, -(CH2)-[CH(CF3)]-(CH2)-, -(CH2)-[C(CH3)CF3]-(CH2)-, -(CH2)-[CH(CH2CF3)]-(CH2)-, -(CH2)-[C(CH3)(CH2CF3)]-(CH2)-, -(CH2)2-(CF2)-O-(CF2)-O-(CF2)-(CH2)2-, -(CH2)-(CF2)-O-(CF2)-O-(CF2)-O-(CF2)-(CH2)-.

[0088] The substituent Y-R2-R1 is particularly preferably selected from the group consisting of O-R2-R1, -R2-R1, and S-R2-R1, wherein -R2- has a meaning as described before or preferably or particularly preferably described before and wherein R1 is a polymerizable group according to formula (5),

wherein

X11 is C(=O)O,

R8 is H or methyl,

R9, R10 are H,

c is 1.



[0089] The substituent Y-R2-R1 is preferably selected from the group consisting of O-R2-R1, -R2-R1 and S-R2-R1, wherein -R2- is selected from the group consisting of -(CH2)3-(CF2)-(CH2)3-, -(CH2)-(CF2)3-(CH2)-, -(CH2)2-(CF2)4-(CH2)2-, -(CH2)-[CH(CF3)]-(CH2)-, -(CH2)-[C(CH3)CF3]-(CH2)-, -(CH2)-[CH(CH2CF3)]-(CH2)-, -(CH2)-[C(CH3)(CH2CF3)]-(CH2)-, -(CH2)2-(CF2)-O-(CF2)-O-(CF2)-(CH2)2-, -(CH2)-(CF2)-O-(CF2)-O-(CF2)-O-(CF2)-(CH2)-,

and wherein R1 is a polymerizable group of formula (5),

wherein

X11 is C(=O)O,

R8 is H or methyl,

R9, R10 are H,

c is 1.



[0090] The alkenyl groups of formula (5) are therefore selected from the group consisting of formulae (5-1) and (5-2):



[0091] The alkenyl group represented by formula (5-1) is called methacrylate. The alkenyl group represented by formula (5-2) is called acrylate.

[0092] The preferred groups R1 are preferably combined with preferred groups of the linking element -R2- and/or the linking element Y-R2-. Combinations are excluded where two O atoms or one O atom and one S atom are directly bonded to each other as known for a skilled artisan in the field of organic chemistry.

[0093] The substituent Y-R2-R1 is therefore particularly preferably selected from the group consisting of
O-(CH2)3-(CF2)-(CH2)3-R1, O-(CH2)-(CF2)3-(CH2)-R1, O-(CH2)2-(CF2)4-(CH2)2-R1, O-(CH2)-[CH(CF3)]-(CH2)-R1, O-(CH2)-[C(CH3)CF3]-(CH2)-R1, O-(CH2)-[CH(CH2CF3)]-(CH2)-R1, O-(CH2)-[C(CH3)(CH2CF3)]-(CH2)-R1, O-(CH2)2-(CF2)-O-(CF2)-O-(CF2)-(CH2)2-R1, O-(CH2)-(CF2)-O-(CF2)-O-(CF2)-O-(CF2)-(CH2)-R1,

wherein R1 is selected from the group consisting of an alkenyl of formula (5-1), or (5-2); -(CH2)3-(CF2)-(CH2)3-R1, -(CH2)-(CF2)3-(CH2)-R1, -(CH2)2-(CF2)4-(CH2)2-R1, - (CH2)-[CH(CF3)]-(CH2)-R1, -(CH2)-[C(CH3)CF3]-(CH2)-R1, -(CH2)-[CH(CH2CF3)]-(CH2)-R1, -(CH2)-[C(CH3)(CH2CF3)]-(CH2)-R1, -(CH2)2-(CF2)-O-(CF2)-O-(CF2)-(CH2)2-R1, -(CH2)-(CF2)-O-(CF2)-O-(CF2)-O-(CF2)-(CH2)-R1,

wherein R1 is selected from the group consisting of an alkenyl of formula (5-1), or (5-2); S-(CH2)3-(CF2)-(CH2)3-R1, S-(CH2)-(CF2)3-(CH2)-R1, S-(CH2)2-(CF2)4-(CH2)2-R1, S-(CH2)-[CH(CF3)]-(CH2)-R1, S-(CH2)-[C(CH3)CF3]-(CH2)-R1, S-(CH2)-[CH(CH2CF3)]-(CH2)-R1, S-(CH2)-[C(CH3)(CH2CF3)]-(CH2)-R1, S-(CH2)2-(CF2)-O-(CF2)-O-(CF2)-(CH2)2-R1, S-(CH2)-(CF2)-O-(CF2)-O-(CF2)-O-(CF2)-(CH2)-R1,

wherein R1 is selected from the group consisting of an alkenyl of formula (5-1), or (5-2).

[0094] Examples for compounds of formula (I') are the following compounds O-001 to O-201:


O-001


O-002


O-003


O-004


O-005


O-006


O-007


O-008


O-009


O-010


O-011


O-012


O-013


O-014


O-015


O-016


O-017


O-018


O-019


O-020


O-021


O-022


O-023


O-024


O-025


O-026


O-027


O-028


O-029


O-030


O-031


O-032


O-033


O-034


O-035


O-036


O-037


O-038


O-039


O-040


O-041


O-042


O-043


O-044


O-045


O-046


O-047


O-048


O-049


O-050


O-051


O-052


O-053


O-054


O-055


O-056


O-057


O-058


O-059


O-060


O-061


O-062


O-063


O-064


O-065


O-066


O-067


O-068


O-069


O-070


O-071


O-072


O-073


O-074


O-075


O-076


O-077


O-078


O-079


O-080


O-081


O-082


O-083


O-084


O-085


O-086


O-087


O-088


O-089


O-090


O-091


O-092


O-093


O-094


O-095


O-096


O-097


O-098


O-099


O-100


O-101


O-102


O-103


O-104


O-105


O-106


O-107


O-108


O-109


O-110


O-111


O-112


O-113


O-114


O-115


O-116


O-117


O-118


O-119


O-120


O-121


O-122


O-123


O-124


O-125


O-126


O-127


O-128


O-129


O-130


O-131


O-132


O-133


O-134


O-135


O-136


O-137


O-138


O-139


O-140


O-141


O-142


O-143


O-144


O-145


O-146


O-147


O-148


O-149


O-150


O-151


O-152


O-153


O-154


O-155


O-156


O-157


O-158


O-159


O-160


O-161


O-162


O-163


O-164


O-165


O-166


O-167


O-168


O-169


O-170


O-171


O-172


O-173


O-174


O-175


O-176


O-177


O-178


O-179


O-180


O-181


O-182


O-183


O-184


O-185


O-186


O-187


O-188


O-189


O-190


O-191


O-192


O-193


O-194


O-195


O-196


O-197


O-198


O-199


O-200


O-201


[0095] The compounds of the present application may be synthesized by methods well known to the skilled person. Preferably, all syntheses are carried out under an inert atmosphere using dried solvents.

[0096] An exemplary reaction sequence is shown in Scheme 1 for the compound 0-105.



[0097] The first type of reaction is a classic Pechmann condensation in acetic anhydride.

[0098] The second type of reaction is an ester hydrolysis.

[0099] The third type is a Mitsunobu reaction.

[0100] The fourth type is an esterification reaction.

[0101] All these types of reaction and their reaction conditions are well known to a skilled person and can be easily optimized for the specific starting materials forming the compounds of formula (I). More details can be found in the experimental section.

[0102] As described before, the compounds of formula (I), (I'), (I") and/or (I'") as described before or preferably described before contain a polymerizable group and are predestinated as monomers for an oligomerization or a polymerization.

[0103] The invention is therefore further directed to an oligomer or polymer comprising polymerized compounds of formula (I), (I'), (I") and/or (I'") as described before or preferably described before.

[0104] The term "polymer" generally means a molecule of high relative molecular mass, the structure of which essentially comprises the multiple repetition of units derived, actually or conceptually, from molecules of low relative molecular mass (PAC, 1996, 68, 2291). The term "polymer" includes homopolymers and co-polymers. The term "oligomer" generally means a molecule of intermediate relative molecular mass, the structure of which essentially comprises a small plurality of units derived, actually or conceptually, from molecules of lower relative molecular mass (PAC, 1996, 68, 2291). In a preferred sense according to the present invention a polymer means a compound having ≥ 30 repeating units, and an oligomer means a compound with > 1 and < 30 repeating units.

[0105] Above and below, in formulae showing a polymer, an oligomer, a compound of formula (I) or a monomeric unit formed from a compound of formula (I), an asterisk ("*") denotes a linkage to the adjacent repeating unit in the polymer chain or oligomer chain or to a terminal end group.

[0106] Suitable terminal end groups are known to the skilled artisan and depend on the polymerization method used.

[0107] The terms "repeating unit" and "monomeric unit" mean the constitutional repeating unit (CRU), which is the smallest constitutional unit the repetition of which constitutes a regular macromolecule, a regular oligomer molecule, a regular block or a regular chain (PAC, 1996, 68, 2291).

[0108] Unless stated otherwise, the molecular weight is given as the number average molecular weight Mn or weight average molecular weight MW, which is determined by gel permeation chromatography (GPC) against polystyrene standards in eluent solvents such as tetrahydrofuran, trichloromethane (TCM, chloroform), chlorobenzene or 1,2,4-trichlorobenzene. Unless stated otherwise, tetrahydrofuran is used as solvent. The degree of polymerization (n) means the number average degree of polymerization given as n = Mn/MU, wherein MU is the molecular weight of the single repeating unit as described in J. M. G. Cowie, Polymers: Chemistry & Physics of Modern Materials, Blackie, Glasgow, 1991.

[0109] In the polymers according to the the present invention, the total number of repeating units n is preferably ≥ 30, very preferably ≥ 100, most preferably ≥ 200, and preferably up to 5000, very preferably up to 3000, most preferably up to 2000, including any combination of the aforementioned lower and upper limits of n.

[0110] The polymers of the present invention include homopolymers, statistical co-polymers, random co-polymers, alternating co-polymers and block co-polymers, and combinations of the aforementioned.

[0111] Throughout the description and claims of this specification, the words "comprise" and "contain" and variations of the words, for example "comprising" and "comprises", mean "including but not limited to", and are not intended to (and do not) exclude other components

[0112] Preferably the polymerizable group R1 forms the regioregular, alternated, regiorandom, statistical, block or random homopolymer or co-polymer backbone or is part of the polymer backbone where R1 has a meaning as described or preferably described before. Particularly preferably, such oligomer or polymer comprises a constitutional unit M0 of formulae (5-p-1),

wherein
-R2-, Y, R3, R4, R5, R6, X, X0, -[B]-, R7, X11, R8, R9, R10 and c have a meaning or a preferred meaning as described or preferably described before. Combinations are excluded where two O atoms or an O atom and a S atom are directly linked to each other as known for a skilled artisan in the field of organic chemistry.

[0113] The co-polymer may be an oligomer or polymer comprising one or more polymerized compounds of formula (I') or a constitutional unit M0 of formula (5-p-1), which may be the same or different from one another, and one or more constitutional units M2, which may be the same or different from one another. Said one or more constitutional units M2 are chemically different from the units M0. Preferably, said one or more constitutional units M2 are derived by polymerization of one or more monomers selected from the group consisting of styrene, ethoxyethyl methacrylate (EOEMA), methyl methacrylate (MMA), n-alkyl acrylates (the n-alkyl group comprising 2-20 C-atoms), n-alkyl methacrylates (the n-alkyl group comprising 2-20 C-atoms), ethoxyethoxy ethylacrylate (EEEA), 2-hydroxyethyl methacrylate (HEMA), tetrahydrofuryl methacrylate (THFMA), glycidylmethacrylate (GMA), 16-hydroxyhexadecyl acrylate, 16-hydroxyhexadecyl methacrylate, 18-hydroxyoctadecyl acrylate, 18-hydroxyoctadecyl methacrylate, 2-phenoxyethyl acrylate (EGPEA), Bisphenol A diacrylate-1 EO/Phenol (BPADA), 2-[3'-2'H-benzotriazol- 2'-yl)-4'-hydroxyphenyl]ethyl methacrylate (BTPEM).

[0114] Alternatively the oligomer or polymer according to the invention is a homopolymer, i.e. an oligomer or polymer comprising one or more constitutional unit M0 of formula of formula (5-p-1), wherein all constitutional units M0 are the same.

[0115] Exemplary polymeric compounds may be selected from the following formulae (P-001) to (P-201):


P-001


P-002


P-003


P-004


P-005


P-006


P-007


P-008


P-009


P-010


P-011


P-012


P-013


P-014


P-015


P-016


P-017


P-018


P-019


P-020


P-021


P-022


P-023


P-024


P-025


P-026


P-027


P-028


P-029


P-030


P-031


P-032


P-033


P-034


P-035


P-036


P-037


P-038


P-039


P-040


P-041


P-042


P-043


P-044


P-045


P-046


P-047


P-048


P-049


P-050


P-051


P-052


P-053


P-054


P-055


P-056


P-057


P-058


P-059


P-060


P-061


P-062


P-063


P-064


P-065


P-066


P-067


P-068


P-069


P-070


P-071


P-072


P-073


P-074


P-075


P-076


P-077


P-078


P-079


P-080


P-081


P-082


P-083


P-084


P-085


P-086


P-087


P-088


P-089


P-090


P-091


P-092


P-093


P-094


P-095


P-096


P-097


P-098


P-099


P-100


P-101


P-102


P-103


P-104


P-105


P-106


P-107


P-108


P-109


P-110


P-111


P-112


P-113


P-114


P-115


P-116


P-117


P-118


P-119


P-120


P-121


P-122


P-123


P-124


P-125


P-126


P-127


P-128


P-129


P-130


P-131


P-132


P-133


P-134


P-135


P-136


P-137


P-138


P-139


P-140


P-141


P-142


P-143


P-144


P-145


P-146


P-147


P-148


P-149


P-150


P-151


P-152


P-153


P-154


P-155


P-156


P-157


P-158


P-159


P-160


P-161


P-162


P-163


P-164


P-165


P-166


P-167


P-168


P-169


P-170


P-171


P-172


P-173


P-174


P-175


P-176


P-177


P-178


P-179


P-180


P-181


P-182


P-183


P-184


P-185


P-186


P-187


P-188


P-189


P-190


P-191


P-192


P-193


P-194


P-195


P-196


P-197


P-198


P-199


P-200


P-201


[0116] The letter n gives the degree of polymerization as explained before.

[0117] Preferably a co-polymer according to the invention as described before or preferably described before comprises the one or more constitutional units M0 in a molar ratio m1 and the one or more constitutional units M2 in a molar ratio m2, wherein the ratio m1 : m2 is at least 0.01 and at most 100.

[0118] The oligomers or polymers according to the invention as described before or preferably described may be cross-linked.

[0119] The oligomers and polymers of the present invention may be made by any suitable method. It is, however, preferred that the present oligomers and polymers are made by radical polymerization, wherein the polymerization reaction is started by means of a suitable radical polymerization initiator. For the purposes of the present invention the type of radical polymerization initiator is not particularly limited and may be any suitable radical generating compound. Such compounds are well known to the skilled person. Suitable polymerization initiators may be selected from thermal initiators or photoinitiators, i.e. compounds that generate radicals by exposure to heat or irradiation with light of a suitable wavelength. Examples of suitable thermal polymerization initiators may be selected from the groups of compounds comprising one or more peroxide groups, i.e. compounds comprising a group -O-O-, and/or compounds comprising one or more azo groups, i.e. compounds comprising a group -N≡N-.

[0120] Suitable polymerization initiators comprising one or more peroxide groups may, for example, be selected from the groups consisting of t-butyl(peroxy-2-ethyl-hexanoate), di-(tert-butylcyclohexyl)peroxydicarbonate and benzoyl peroxide.

[0121] Suitable polymerization initiators comprising one or more azo groups may, for example, be selected from the group consisting of 1,1'-azobis(cyclohexancarbonitrile) and 2,2'azobis(cyclohexanecarbonitrile) (AIBN).

[0122] A suitable example of a photoinitiator is dimethylaminobenzoate /camphorquinone.

[0123] If a photoinitiator is used as polymerization initiator, it is preferred that the wavelength required to decompose said photoinitiator is different from the wavelength needed to irradiate the compound of the present application so as to change its optical properties.

[0124] Preferably, the radical initiators are used in an amount of at least 0.0001 eq and of at most 0.1 eq of the main monomer. Such radical initiators could be thermal initiators, e.g. azobisisobutyronitrile (AIBN) or photochemical initiators like dimethylaminobenzoate/camphorquinone.

[0125] The present invention is also directed to a composition comprising at least one compound of formula (I') as described or preferably described before and/or an oligomer or polymer as described before or preferably described before.

[0126] A composition comprising at least one compound of formula (I') as described or preferably described before and an oligomer or polymer as described before is primarily used for the synthesis of block co-polymers with the condition that the oligomer or polymer has at least one reactive group left which may react with the monomers.

[0127] Depending upon the intended use such composition may comprise further different components. Such further components may, for example, be selected from the group consisting of UV absorbers, antioxidants and cross-linkers.

[0128] The compositions may include or comprise, essentially consist of or consist of the said requisite or optional constituents. All compounds or components which can be used in the compositions are either known and commercially available or can by synthesized by known processes.

[0129] The UV absorber that may be used in the present composition is not particularly limited and can easily be selected from those generally known to the skilled person. Generally suitable UV absorbers are characterized by being unsaturated compounds, preferably compounds comprising one or more selected from group consisting of olefinic groups, aryl groups and heteroaryl groups; these groups may be present in any combination.

[0130] Suitable UV-absorbers for use in the present composition may, for example, be selected from those comprising a group selected from benzotriazole, benzophenone and triazine. Suitable UV-absorbers are, for example, disclosed in U.S. Pat. Nos. 5,290,892; 5,331,073 and 5,693,095.

[0131] Suitable cross-linkers may be used to impart elastomeric properties to the present composition and the articles produced therewith. Typically any suitable di- or tri-functional monomer may be used as crosslinker. Such monomers are generally well known to the skilled person.

[0132] Preferred cross-linker may be selected from the following group of compounds



[0133] Ethylene glycol dimethacrylate (EGDMA) is particularly preferred.

[0134] Suitable antioxidants are phenyl acrylate derivatives bearing a hindered phenol moiety. A preferred antioxidant is



[0135] The compounds of formula (I) according to the invention and their oligomers or polymers as described before or preferably described before are particularly well suited for use in optically active devices.

[0136] Hence the present invention is also directed to articles e.g. blanks which may be transformed into optically active devices comprising at least one compound of formula (I) as described before or preferably described before or at least one oligomer or polymer as described before or preferably described before.

[0137] Preferred articles are blanks which may be transformed into optically active devices or the optically active devices as such. Preferred optically active devices are ophthalmic devices. Examples of such ophthalmic devices include lenses, keratoprostheses, and cornea inlays or rings. More preferably, said article is a blank which may be transformed into an eye-implant or the eye-implant as such. More preferably, said eye-implant is a lens. Most preferably, such article is a blank which may be transformed into an intraocular lens or the intraocular lens as such, which may, for example, be a posterior chamber intraocular lens or an anterior chamber intraocular lens.

[0138] A blank of this invention may be produced as a step in the manufacturing process used to create an intraocular lens. For example, without limitation, a manufacturing process may include the steps of polymer synthesis, polymer sheet casting, blank cutting, optic lathe cutting, optic milling, haptic milling or attachment, polishing, solvent extraction, sterilization and packaging.

[0139] The present articles according to the invention as described before or preferably described before may be formed by a process comprising the steps of
  • providing a composition comprising at least one compound of formula (I) as described herein or preferably described herein and/or an oligomer or polymer as described herein or preferably described herein; and
  • subsequently forming the article of said composition.


[0140] Intraocular lenses in accordance with the present invention are believed to show particularly advantageous properties in that they are flexible enough so as to be rolled or folded and consequently requiring a much smaller incision for them to be inserted into the eye. It is believed that this will allow for improved healing of the eye, particularly in respect to the time for the eye to heal.

[0141] The type of intraocular lens is not limited in any way. It may, for example, comprise one or more optic and one or more haptic components, wherein the one or more optic components serve as lens and the one or more haptic components are attached to the one or more optic components and hold the one or more optic components in place in the eye. The present intraocular lens may be of a one-piece design or of multi-piece design, depending on whether the one or more optic components and the one or more haptic components are formed from a single piece of material (one-piece design) or are made separately and then combined (multi-piece design). The present intraocular lens is also designed in such a way that it allows to be, for example, rolled up or folded small enough so that it fits through an incision in the eye, said incision being as small as possible, for example, at most 3 mm in length.

[0142] Additionally, intraocular lenses in accordance with the present invention allow for the non-invasive adjustment of the optical properties, particularly the refractive power, after implantation of the lens into the eye, thus reducing the need for post-surgery vision aids or reducing or totally avoiding follow-up surgery.

[0143] In order to change the optical properties and particularly the refractive power of the intraocular lens it is exposed to irradiation having a wavelength of at least 200 nm and of at most 1500 nm. Hence, the present invention is also directed to a process of changing the optical properties of an article as defined or preferably defined herein, said process comprising the steps of
  • providing an article as defined herein; and
  • subsequently exposing said article to irradiation having a wavelength of at least 200 nm and at most 1500 nm.


[0144] Preferably, said irradiation has a wavelength of at least 250 nm or 300 nm, more preferably of at least 350 nm, even more preferably of at least 400 nm, still even more preferably of at least 450 nm, and most preferably of at least 500 nm. Preferably, said irradiation has a wavelength of at most 1400 nm or 1300 nm or 1200 nm or 1100 nm or 1000 nm, more preferably of at most 950 nm or 900 nm, even more preferably of at most 850 nm, still even more preferably of at most 800 nm and most preferably of at most 750 nm.

Examples



[0145] The following examples are intended to show the advantages of the present compounds in a non-limiting way.

[0146] Unless indicated otherwise, all syntheses are carried out under an inert atmosphere using dried (i.e. water-free) solvents. Solvents and reagents are purchased from commercial suppliers.

[0147] DCM is used to denote dichloromethane. DMF is used to denote dimethylformamide. EE is used to denote ethyl acetate. THF is used to denote tetrahydrofuran.

[0148] Co-polymer-properties can be investigated on blanks, prepared by bulk polymerization of the monomers. Co-monomers, cross-linkers and initiators therefore can be purchased from commercial sources. All chemicals are of highest purity available and can be used as received.

Synthesis of precursor materials:


General remarks & general synthetic procedures (GSP) - Trifluormethylation or trifluorethylation of carbon nucleophiles:



[0149] The introduction of a trifluormethyl- or trifluoroethyl group to the corresponding carbon nucleophile is performed with 3,3-dimethyl-1-(trifluoromethyl)-1,2-benziodoxole, 5-(trifluoromethyl)dibenzothiophenium triflate as well as phenyl(2,2,2-trifluoroethyl)iodonium bis((trifluoromethyl)sulfonyl)amid. The experimental procedures for this reactions can be found under the following DOI numbers: 10.1021/jo981065b, 10.1002/chem.200501052, 10.1021/ja00059a009.

Characterization of precursor materials:


Diethyl 2-methylmalonat:



[0150] 

1H NMR (500 MHz, CDCl3) δ 4.23-4.16 (m, 4H), 3.41 (q, 1H, J = 7.3 Hz), 1.41 (d, 3H, J = 7.3 Hz), 1.27 (t, 6H, J = 7.1 Hz).

2,2,3,3,4,4-hexafluoro-5-hydroxypentyl acrylate:



[0151] 



[0152] This compound is synthesized based on the procedure described in US 2012/308802, preparation example 1, [0071].
1H NMR (500 MHz, CDCl3) δ 6.52 (dd, 1H, J1 = 17.3 Hz, J2 = 1.1 Hz), 6.18 (dd, 1H, J1 = 17.3 Hz, J2 = 10.5 Hz), 5.97 (dd, 1H, J1 = 10.5 Hz, J2 = 1.1 Hz), 4.66 (t, 2H, J = 14.1 Hz), 4.12-4.05 (m, 2H), 1.97 (t, 1H, J = 7.5 Hz).

Example 1:


General remarks & general synthetic procedures (GSP 1) for the synthesis of acetic acid 3-phenyl-coumarin-7-yl ester:



[0153] 



[0154] 2 g (14.2 mmol) 2,4-Dihydroxy-benzaldehyde and 3.1 g (14.2 mmol) 4 bromophenyl-acetic acid are dissolved in 4.5 ml acetic anhydride and 4.4 ml pyridine. The batch is stirred at 135 °C for 72 h and is then cooled to room temperature. The solid which has precipitated out is filtered off with suction and rinsed neutral with water. The residue is dried at 40 °C in vacuo. The yield of 3-(4-bromophenyl)-2-oxo-2H-chromen-7-yl acetate is 4.9 g (13.6 mmol) (96% of theory).
1H NMR (500 MHz, DMSO-d6) δ 8.31 (s, 1H), 7.82 (d, 1H, J = 8.5 Hz), 7.71-7.66 (m, 4H), 7.32 (d, 1H, J = 2.0 Hz), 7.20 (dd, 1H, J = 8.4 Hz, J = 2.1 Hz), 2.32 (s, 3H).

[0155] Analogously, other derivatives are prepared in the same manner: R1 means reactant 1, R2 means reactant 2, [P] means product
No.  Yield [%]
1a R1

 
  R2

 
  [P]

68
1b R1

 
  R2

 
  [P]

89
1c R1

 
  R2

 
  [P]

57
1d R1

 
  R2

 
  [P]

73
1e R1

 
  R2

 
  [P]

99
1f R1

 
  R2

 
  [P]

64
1g R1

 
  R2

 
  [P]

69
1h R1

 
  R2

 
  [P]

60
1i R1

 
  R2

 
  [P]

65
1j R1

 
  R2

 
  [P]

69
1k R1

 
  R2

 
  [P]

75
1l R1

 
  R2

 
  [P]

91
1m R1

 
  R2

 
  [P]

69
1n R1

 
  R2

 
  [P]

67
1o R1

 
  R2

 
  [P]

58
1p R1

 
  R2

 
  [P]

62


1H NMR (500 MHz, CDCl3) δ 8.31 (m, 2H), 7.47 (dd, 1H, J = 8.2 Hz, J = 1.8 Hz), 7.43 (d, 1H, J = 8.3 Hz), 7.29 (d, 1H, J = 8.2 Hz), 6.89 (d, 2H, J = 8.4 Hz), 3.90 (s, 3H).

1H NMR (500 MHz, DMSO-d6) δ 8.08 (s, 1H), 7.74 (s, 1H), 7.69 (d, 1H, J = 8.7 Hz), 7.54 (s, 2H), 7.08 (d, 1H, J = 2.3 Hz), 7.01 (dd, 1H, J = 8.6 Hz, J = 2.4 Hz), 3.89 (s, 3H).

1H NMR (500 MHz, CDCl3) δ 7.77 (d, 2H, J = 2.1 Hz), 7.63 (s, 1H), 7.60 (dd, 1H, J = 8.2 Hz, J = 2.2 Hz), 7.53 (d, 1H, J = 8.4 Hz), 7.36 (d, 1H, J = 8.2 Hz), 7.19 (d, 1H, J = 2.1 Hz), 7.10 (dd, 1H, J = 8.5 Hz, J = 2.2 Hz), 2.36 (s, 3H).

1H NMR (500 MHz, DMSO-d6) δ 8.08 (s, 1H), 7.87 (d, 1H, J = 7.8 Hz), 7.83 (d, 1H, J = 8.5 Hz), 7.78 (t, 1H, J = 7.5 Hz), 7.69 (t, 1H, J = 7.7 Hz), 7.59 (d, 1H, J = 7.6 Hz), 7.38 (d, J = 2.1 Hz), 7.23 (dd, J = 8.4 Hz, J = 2.2 Hz), 2.34 (s, 3H).

1H NMR (500 MHz, CDCl3) δ 7.67 (d, 1H, J = 2.2 Hz), 7.51-7.47 (m, 2H), 7.45 (d, 2H, J = 8.3 Hz), 7.23 (d, 1H, J = 8.2 Hz), 6.91-6.89 (m, 2H), 3.84 (s, 3H).

1H NMR (500 MHz, CDCl3) δ 7.71 (s, 1H), 7.57-7.54 (m, 2H), 7.43 (d, 2H, J = 8.5 Hz), 6.97-6.95 (m, 2H), 3.90 (s, 3H).

1H NMR (500 MHz, CDCl3) δ 8.21 (s, 1H), 7.84 (d, 1H, J = 8.5 Hz), 7.79-7.72 (m, 2H), 7.58 (d, 1H, J = 8.7 Hz), 7.37 (d, 1H, J = 2.1 Hz), 7.22 (dd, 1H, J = 8.4 Hz, J = 2.2 Hz), 2.33 (s, 3H).

1H NMR (500 MHz, CDCl3) δ 7.74 (s, 1H), 7.54 (d, 1H, J = 8.5 Hz), 7.51 (dd, 1H, J = 7.8 Hz, J = 1.7 Hz), 7.49-7.44 (m, 1H), 7.40-7.35 (m, 3H), 7.18 (d, 1H, J = 2.1 Hz), 7.38 (d, J = 2.1 Hz), 7.09 (dd, J = 8.4 Hz, J = 2.2 Hz), 2.36 (s, 3H).

1H NMR (500 MHz, CDCl3) δ 7.74 (d, 2H, J = 8.8 Hz), 7.56 (d, 1H, J = 8.5 Hz), 7.30 (d, 2H, J = 8.2 Hz), 7.17 (d, 1H, J = 2.1 Hz), 7.09 (dd, 1H, J = 8.4 Hz, J = 2.2 Hz), 2.35 (s, 3H).

1H NMR (500 MHz, CDCl3) δ 7.74 (d, 2H, J = 8.8 Hz), 7.50 (d, 1H, J = 8.5 Hz), 7.50-7.47 (m, 2H), 7.15 (d, 1H, J = 2.2 Hz), 7.07 (dd, 1H, J = 8.4 Hz, J = 2.2 Hz), 6.86 (d, 1H, J = 8.8 Hz), 3.81 (s, 3H), 2.35 (s, 3H).

1H NMR (500 MHz, CDCl3) δ 7.70 (d, 2H, J = 8.8 Hz), 7.50 (d, 1H, J = 8.5 Hz), 7.24 (d, 1H, J = 8.1 Hz), 7.18 (dd, 1H, J = 8.1 Hz, J = 1.8 Hz), 7.14 (dd, 1H, J = 10.4 Hz, J = 2.0 Hz), 7.07 (dd, 1H, J = 8.4 Hz, J = 2.2 Hz), 3.81 (s, 3H), 2.35 (s, 3H).

1H NMR (500 MHz, CDCl3) δ 7.77 (d, 2H, J = 2.2 Hz), 7.65 (s, 1H), 7.61 (dd, 1H, J = 8.2 Hz, J = 2.2 Hz), 7.55 (d, 1H, J = 8.0 Hz), 7.48 (d, 1H, J = 1.6 Hz), 7.39-7.34 (m, 2H), 2.50 (s, 3H).

Example 2:


General remarks & general synthetic procedures (GSP 2) for the deprotection of the acetate derivative to the phenol derivative:



[0156] 



[0157] 7.0 mmol acetic acid 3-phenyl-coumarin-7-yl ester are suspended in a mixture of 14 ml ethanol and 10 ml sulfuric acid (20%, aq.) and refluxed for 2 h. The batch is then cooled to room temperature, and the precipitated solid is filtered off with suction and rinsed neutral with water. The yield is 6.8 mmol, 97% of theory.
1H NMR (500 MHz, DMSO-d6) δ 10.59 (s, 1H), 8.16 (s, 1H), 7.70 (dd, 2H, J = 7.3 Hz, J = 1.7 Hz), 7.61 (d, 1H, J = 8.5 Hz), 7.45 (t, 2H, J = 7.5 Hz), 7.39 (t, 1H, J = 7.3 Hz), 6.83 (dd, 1H, J = 8.5 Hz, J = 2.2 Hz), 6.77 (d, 1H, J = 2.2 Hz).

[0158] Analogously, other 7-hydroxy-3-phenyl-coumarin derivatives are prepared in the same manner:
No.ReactantProductYield [%]
2a



99
2b



90
2c



89
2d



99
2e



80
2f



59
2g



75
2h



89


1H NMR (500 MHz, DMSO-d6) δ 10.56 (s, 1H), 8.12 (s, 1H), 7.61 (d, J = 8.2 Hz, 2H), 7.59 (d, J = 8.6 Hz, 1H), 7.25 (d, J = 8.1 Hz, 2H), 6.83 (dd, J = 8.5 Hz, 2.2 Hz, 1H), 6.76 (d, J = 2.1 Hz, 1H), 2.61 (t, J = 7.6 Hz, 2H), 1.60 (p, J = 7.5 Hz, 2H), 1.37 - 1.36 (m, 4H), 0.88 (t, J = 7.0 Hz, 3H).

1H NMR (500 MHz, DMSO-d6) δ 10.65 (s, 1H), 7.92 (s, 1H), 7.84 (d, J = 7.9 Hz, 1H), 7.75 (t, J = 7.5 Hz, 1H), 7.66 (t, J = 7.7 Hz, 1H), 7.59 (d, J = 8.5 Hz, 1H), 7.54 (d, J = 7.6 Hz, 1H), 6.84 (dd, J = 8.5 Hz, 2.3 Hz, 1H), 6.80 (d, J = 2.2 Hz, 1H).

1H NMR (500 MHz, DMSO-d6) δ 10.64 (s, 1H), 7.86 (s, 1H), 7.80 - 7.75 (m, 2H), 7.70 (t, J = 7.4 Hz, 1H), 7.58 (d, J = 8.5 Hz, 1H), 7.52 (d, J = 7.3 Hz, 1H), 6.84 (dd, J = 8.5 Hz, 2.3 Hz, 1H), 6.79 (d, J = 2.2 Hz, 1H).

1H NMR (500 MHz, DMSO-d6) δ 10.63 (s, 1H), 7.89 (s, 1H), 7.63 (s, 1H), 7.57 (d, J = 8.5 Hz, 1H), 7.56 (d, J = 7.7 Hz, 1H), 7.42 (d, J = 7.8 Hz, 1H), 6.83 (dd, J = 8.5 Hz, 2.2 Hz, 1H), 6.79 (d, J = 2.2 Hz, 1H), 2.76 - 2.69 (m, 2H), 1.64 (p, J = 7.5 Hz, 2H), 1.40 1.26 (m, 4H), 0.89 (t, J = 6.9 Hz, 3H).

1H NMR (500 MHz, DMSO-d6) δ 10.51 (s, 1H), 8.08 (s, 1H), 7.65 (d, J = 8.9 Hz, 2H), 7.59 (d, J = 8.5 Hz, 1H), 6.99 (d, J = 8.9 Hz, 2H), 6.82 (dd, J = 8.5 Hz, 2.3 Hz, 1H), 6.75 (d, J = 2.2 Hz, 1H), 4.02 (t, J = 6.5 Hz, 2H), 1.78 - 1.66 (m, 2H), 1.51 - 1.41 (m, 2H), 0.95 (t, J = 7.4 Hz, 2H).

1H NMR (500 MHz, CDCl3) δ 7.77 (d, J = 2.0 Hz, 1H), 7.61 (dd, J = 8.4 Hz, 2.2 Hz, 1H), 7.60 (s, 1H), 7.40 - 7.36 (m, 2H), 7.28 (d, J = 1.4 Hz, 1H), 7.18 (dd, J = 8.1 Hz, 1.7 Hz, 1H), 3.80 (s, 1H).

1H NMR (500 MHz, DMSO-d6) δ 10.68 (s, 1H), 8.23 (s, 1H), 7.84 (d, J = 8.8 Hz, 2H), 7.62 (d, J = 8.5 Hz, 1H), 7.45 (d, J = 8.2 Hz, 2H), 6.85 (dd, J = 8.5 Hz, 2.3 Hz, 1H), 6.78 (d, J = 2.2 Hz, 1H).

1H NMR (500 MHz, DMSO-d6) δ 10.68 (s, 1H), 8.04 (s, 1H), 7.61 (d, J = 8.5 Hz, 1H), 7.57 (td, J = 7.4 Hz, 1.7 Hz, 1H), 7.49 (dd, J = 7.2 , 1.3 Hz, 1H), 7.46 (d, J = 7.6 Hz, 1H), 6.85 (dd, J = 8.5 Hz, 2.3 Hz, 1H), 6.80 (d, J = 2.1 Hz, 1H).

Example 3:


General remarks & general synthetic procedures (GSP 3) for the reduction of aliphatic diesters or diketones to the corresponding diols:



[0159] 



[0160] Solid, fine powdered lithiumaluminium hydride (2.0 - 5.0 equiv.) is suspended in dry THF at room temperature. The corresponding diacid- or diester derivative is dissolved in dry THF and the solution is slowly added dropwise to the lithiumaluminium slurry while cooling with an ice bath. After complete addition, the reaction solution is warmed to room temperature and the consumption of the starting material is checked by TLC. The suspension is carefully quenched with 2M H2SO4, additional water is added. For a better workup, the suspension should have a pH of ~7. The phases are separated and extracted with Et2O. The organic phase is washed with H2O, dried over MgSO4 and evaporated under reduced pressure. The crude product is directly used without further purification or purified via column chromatography using cyclohexane/tert-butyl methyl ether.
1H NMR (500 MHz, CDCl3) δ 3.70 (t, 4H, J = 6.3 Hz), 2.00-1.90 (m, 4H), 1.79-1.74 (m, 4H), 1.38 (br s, 2H).

[0161] Analogously, other diol derivatives are prepared in the same manner:
No.Starting MaterialProductYield [%]
3a



70
3b



49
3c



41
3d



35
3e



88
3f



86
3g



53

Example 4:


General remarks & general synthetic procedures (GSP 4) for the Suzuki coupling of halogenated 2-oxo-3-phenyl-2H-chromen-7-yl acetate derivatives:



[0162] 



[0163] 3.0 g (8.4 mmol) of acetic acid 3-(4-bromophenyl)-coumarin-7-yl ester, 1.0 g (8.8 mmol) of n-pentylboronic acid and 3.7 g (17.5 mmol) of tripotassium phosphate trihydrate are dissolved in 80 ml of toluene and degassed. 171 mg (0.4 mmol) of 2-dicyclohexylphoshino-2',6'-dimethoxy-1,1 '-biphenyl [S-Phos] and 47 mg (0.2 mmol) of palladium(II) acetate are added. The reaction mixture is subsequently stirred at 110 °C for 24 h under a protective-gas atmosphere. The cooled solution is diluted with ethyl acetate and washed with water, dried and evaporated. The product is purified by column chromatography on silica gel (heptane/ethyl acetate). Yield: 2.5 g (7.1 mmol), 85% of theory.

[0164] Under the basic conditions, deprotection of the acetate group to the corresponding phenol could be observed during several Suzuki coupling reactions. To complete the deprotection step, the crude organic phase after workup is refluxed with a 1:2 mixture sulfuric acid (~20%):ethanol until completion. Then column chromatography of the obtained residue, as described above, is done.
1H NMR (500 MHz, DMSO-d6) δ 8.23 (s, 1H), 7.81 (d, 1H, J = 8.4 Hz), 7.64 (d, 2H, J = 8.2 Hz), 7.34-7.25 (m, 3H), 7.18 (dd, 1H, J = 8.4 Hz, J = 2.2 Hz), 7.20 (dd, 1H, J = 8.4 Hz, J = 2.1 Hz), 2.62 (t, 2H, J = 7.6 Hz), 2.32 (s, 3H), 1.64-1.58 (m, 2H), 1.37-1.24 (m, 4H), 0.87 (t, 3H, J = 7.0 Hz).

[0165] Analogously, other Suzuki derivatives are prepared in the same manner: R1 means reactant 1, R2 means reactant 2, [P] means product
No.  Yield [%]
4a R1

 
  R2

 
  [P]

85
4b R1

 
  R2

 
  [P]

94
4c R1

 
  R2

 
  [P]

92
4d R1

 
  R2

 
  [P]

90
4e R1

 
  R2

 
  [P]

90
4f R1

 
  R2

 
  [P]

95
4g R1

 
  R2

 
  [P]

84
4i R1

 
  R2

 
  [P]

95
4j R1

 
  R2

 
  [P]

28
4k R1

 
  R2

 
  [P]

79
4l R1

 
  R2

 
  [P]

62


1H NMR (500 MHz, CDCl3) δ 7.62 (s, 1H), 7.57 (d, 1H, J = 1.7 Hz), 7.51 (d, 1H, J = 8.5 Hz), 7.44-7.38 (m, 1H), 7.30 (d, 1H, J = 7.8 Hz), 7.17 (d, 1H, J = 2.2 Hz), 7.08 (dd, 1H, J = 8.4 Hz, J = 2.2 Hz), 2.70 (t, 2H, J = 8.7 Hz), 2.36 (s, 3H), 1.71-1.62 (m, 2H), 1.38-1.35 (m, 4H), 0.92 (m, 3H).

1H NMR (500 MHz, CDCl3) δ 7.72 (s, 1H), 7.54 (d, 1H, J = 9.4 Hz), 7.46 (d, 2H, J = 7.7 Hz), 7.23 (d, 2H, J = 7.8 Hz), 6.95 (d, 2H, J = 7.0 Hz), 3.90 (s, 3H), 2.64 (t, 2H, J = 7.7 Hz), 1.65 (t, 2H, J = 7.6 Hz), 1.36-1.33 (m, 4H), 0.90 (t, 3H, J = 7.0 Hz).

1H NMR (500 MHz, CDCl3) δ 7.69 (d, 1H, J = 9.9 Hz), 7.40 (d, 2H, J = 8.0 Hz), 7.18-7.15 (m, 2H), 6.96 (d, 1H, J = 2.2 Hz), 6.83 (dd, 1H, J = 8.5 Hz, J = 2.3 Hz), 5.98 (d, 1H, J = 9.2 Hz), 2.71-2.61 (m, 2H), 1.69-1.60 (m, 2H), 1.37-1.34 (m, 4H), 0.91 (t, 3H, J = 6.9 Hz).

1H NMR (500 MHz, CDCl3) δ 7.70 (s, 1H), 7.40 (dd, 2H, J = 8.0 Hz, J = 6.3 Hz), 7.20 (d, 2H, J = 7.9 Hz), 6.98 (d, 1H, J = 2.4 Hz), 6.84 (dd, 1H, J = 8.5 Hz, J = 2.4 Hz), 6.84 (br s, 1H), 3.70 (s, 3H), 2.71 (q, 2H, J = 7.6 Hz), 1.28 (t, 3H, J = 7.6 Hz).

1H NMR (500 MHz, DMSO-d6) δ 10.52 (s, 1H), 7.86 (s, 1H), 7.54 (d, 2H, J = 8.5 Hz), 7.18 (dd, 1H, J = 8.4 Hz, J = 2.3 Hz), 7.10 (d, 1H, j = 2.2 Hz), 6.98 (d, 1H, J = 8.4 Hz), 6.79 (dd, 1H, J = 8.5 Hz, J = 2.3 Hz), 6.74 (d, 1H, J = 2.2Hz), 3.71 (s, 3H), 2.55-2.51 (m, 2H), 1.56 (p, 2H, J = 7.4 Hz),1.35-1.26 (m, 4H), 0.88-0.84 (m, 3H).

1H NMR (500 MHz, DMSO-d6) δ 10.50 (s, 1H), 7.85 (s, 1H), 7.54 (d, 2H, J = 8.5 Hz), 7.19 (d, 1H, J = 7.6 Hz), 7.10 (d, 1H, j = 2.2 Hz), 6.92 (d, 1H, J = 1.5 Hz), 6.83 (dd, 1H, J = 7.5 Hz, J = 1.5 Hz), 6.80 (dd, 1H, J = 8.4 Hz, J = 2.3Hz), 6.74 (d, 1H, J = 2.3 Hz), 3.74 (s, 3H), 2.64-2.57 (m, 2H), 1.63 (p, 2H, J = 7.4 Hz),1.37-1.31 (m, 4H), 0.90 (t, 3H, J = 6.9 Hz).

1H NMR (500 MHz, CDCl3) δ 8.08 (s, 1H), 7.74 (s, 1H), 7.69 (d, 1H, J = 8.7 Hz), 7.54 (s, 2H), 7.08 (d, 1H, J = 2.3 Hz), 7.01 (dd, 1H, J = 8.6 Hz, J = 2.4 Hz), 3.98 (s, 3H), 2.74 (q, 2H, J = 7.8 Hz), 2.63-2.56 (m, 2H), 1.32 (t, 3H, J = 7.6 Hz), 1.18 (t, 3H, J = 7.5 Hz).

1H NMR (500 MHz, CDCl3) δ 8.04 (s, 1H), 7.71-7.66 (m, 2H), 7.62 (d, 1H, J = 8.0 Hz), 7.48 (d, 1H, J = 7.9 Hz), 7.08 (d, 1H, J = 2.4 Hz), 7.01 (dd, 1H, J = 8.6 Hz, J = 2.4 Hz), 3.89 (s, 3H), 2.62 (q, 2H, J = 7.5 Hz), 1.11 (t, 3H, J = 7.5 Hz).

Example 5:


General remarks & general synthetic procedures (GSP 5) for the deprotection of the methyl ether derivatives to the corresponding phenol derivatives:



[0166] 



[0167] To a solution of 3-(2-ethyl-4-pentylphenyl)-7-methoxy-2H-chromen-2-one (300 mg, 0.973 mmol) in 10 ml DCM is added BCl3 (2.0 equiv.) at 0 °C. The solution is warmed to room temperature overnight and refluxed for additional one hour. After cooling down the reaction mixture to room temperature, it is poured on an ice/water mixture, extracted with EE, dried with MgSO4 and evaporated. The residue is purified via column chromatography using heptane / EE as eluent. 182.3 mg (0.51 mmol) of 3-(2-ethyl-4-pentylphenyl)-7-hydroxy-2H-chromen-2-one is isolated (83% of theory).

[0168] Alternatively, the deprotection of the methylethers may be done in the presence of BBr3.
1H NMR (500 MHz, DMSO-d6) δ 10.58 (s, 1H), 7.85 (s, 1H), 7.54 (d, 2H, J = 8.5 Hz), 7.16 7.06 (m, 3H), 7.10 (d, 1H, j = 2.2 Hz), 6.81 (dd, 1H, J = 8.5 Hz, J = 2.3 Hz), 6.76 (d, 1H, J = 2.3 Hz), 2.63 (q, 2H, J = 7.6 Hz), 2.49-2.45 (m, 2H), 1.21 (t, 3H, J = 7.6 Hz), 1.07 (t, 3H, J = 7.5 Hz).

[0169] Analogously, other phenol derivatives are prepared in the same manner:
No.Reactant 1ProductYield [%]
5a



Quant.
5b



83
5c



75


1H NMR (500 MHz, CDCl3) δ 10.62 (s, 1H), 8.00-7.97 (m, 1H), 7.87 (d, 1H, J = 2.5 Hz), 7.82 (dd, 1H, J = 8.2 Hz, J '= 2.5 Hz), 7.57 (d, 1H, J = 8.5 Hz), 7.37 (d, 1H, J = 8.2 Hz), 6.84 (dd, 1H, J = 8.5 Hz, J = 2.3 Hz), 6.79 (d, 1H, J = 2.2 Hz), 2.60 (q, 2H, J = 7.4 Hz), 1.15-1.09 (m, 3H).

1H NMR (500 MHz, CDCl3) δ 10.58 (s, 1H), 7.87 (s, 1H), 7.56 (d, 1H, J = 8.5 Hz), 7.13 7.06 (m, 2H), 6.82 (dd, 1H, J = 8.5 Hz, J = 2.3 Hz), 6.78 (d, 1H, J = 2.2 Hz), 2.63 (q, 2H, J = 7.6 Hz), 2.48 (q, 2H, J = 7.5 Hz), 1.22 (t, 3H, J = 7.6 Hz), 1.08 (t, 3H, J = 7.5 Hz).

Example 6:


General remarks & general synthetic procedures (GSP 6) for the reaction of the corresponding fluorinated diols or monoalcohol with 7-hydroxy-3-phenyl-2H-chromen-2-one derivatives (Mitsunobu alkylation type reaction):



[0170] 



[0171] To an ice-cooled solution of 2-phenylbenzofuran-6-ol, aliphatic fluorinated diol or monoalcohol (1.0 equiv.) and triphenylphosphine in THF (1.43 equiv.), diisopropyl azodicarboxylate (1.43 equiv.) is added dropwise. After stirring at room temperature overnight, the reaction mixture is evaporated. The crude product is purified by column chromatography (cyclohexane / EE).

[0172] Analogously, other derivatives are prepared in the same manner: R1 means reactant 1, R2 means reactant 2, [P] means product
No.  Yield [%]
6a R1

 
  R2

 
  [P]

58
6b R1

 
  R2

 
  [P]

52
6c R1

 
  R2

 
  [P]

48
6d R1

 
  R2

 
  [P]

66
6e R1

 
  R2

 
  [P]

60
6f R1

 
  R2

 
  [P]

58
6g R1

 
  R2

 
  [P]

73
6h R1

 
  R2

 
  [P]

16
6i R1

 
  R2

 
  [P]

42
6j R1

 
  R2

 
  [P]

32
6k R1

 
  R2

 
  [P]

21
6l R1

 
  R2

 
  [P]

19


1H NMR (500 MHz, CDCl3) δ 7.77 (s, 1H), 7.73-7.63 (m, 2H), 7.48-7.42 (m, 3H), 7.39 (t, 1H, J = 7.3 Hz), 6.91-6.85 (m, 2H), 4.35 (t, 2H, J = 6.7 Hz), 4.01 (q, 2H, J = 6.2 Hz), 2.73 2.63 (m, 2H), 2.46-2.36 (m, 2H), 1.57 (t, 1H, J = 5.9 Hz).

1H NMR (500 MHz, CDCl3) δ 7.76 (s, 1H), 7.69 (d, 2H, J = 7.7 Hz), 7.46-7.41 (m, 3H), 7.40-7.34 (m, 2H), 6.87-6.85 (m, 2H), 4.04 (t, 2H, J = 6.5 Hz), 1.86-1.76 (m, 3H), 1.56-1.48 (m, 2H), 1.00 (t, 3H, J = 7.4 Hz).

Example 7:


General remarks & general synthetic procedures (GSP 7) for the reaction of bromo-functionalized hydrophic linkers with 7-mercapto-2-phenyl-2H-chromen-2-one derivatives:



[0173] For the reaction of thiols with the fluorinated aliphatic linker, the bromo-functionalized derivatives of the corresponding diols is prepared in advance through reaction of the corresponding diol with HBr in refluxing toluene.



[0174] 7-mercapto-3-(4-pentyl-2-(trifluoromethyl)phenyl)-2H-chromen-2-one and 8-bromo-3,3,4,4,5,5,6,6-octafluorooctan-1-ol (1.05 equiv.) are dissolved in anhydrous DMF. Then, K2CO3 (4.0 equiv.) is added and the suspension is heated up to reflux until completion of the reaction. The reaction mixture is filtrated and the separated solid is thoroughly washed with additional acetone. The filtrate is concentrated in vacuo and the crude product is purified via column chromatography using cyclohexane / EE as an eluent. 7-((3,3,4,4,5,5,6,6-octafluoro-8-hydroxyoctyl)thio)-3-(4-pentyl-2-(trifluoromethyl)phenyl)-2H-chromen-2-one isolated in 76% yield (of theory) as a pale beige solid.

[0175] Analogously, other derivatives are prepared in the same manner: R1 means reactant 1, R2 means reactant 2, [P] means product
7a R1

 
  R2

 
  [P]

37

Preparation of compounds according to the invention:


Example 8:


General remarks & general synthetic procedures (GSP 8) for the esterification with acryloyl chloride or methacryloyl chloride to the corresponding monomer:



[0176] 



[0177] The corresponding aliphatic alcohol is dissolved in dry THF and the solution is cooled with an ice-bath. Triethylamine (4.00 equivs.) is added and the solution is stirred for a few minutes. Then acryloyl chloride or methacryloyl chloride (1.05 - 2.00 equivs.) is added at ice-bath temperature, while precipitating a colourless solid. The solution is stirred for several hours and is monitored via TLC. Upon completion of the reaction, the suspension is filtrated and washed with THF. The filtrate is evaporated under reduced pressure and purified via column chromatography using cyclohexane / ethyl acetate.
1H NMR (500 MHz, CDCl3) δ 7.76 (s, 1H), 7.73-7.65 (m, 2H), 7.45-7.43 (m, 3H), 7.40-7.37 (m, 1H), 6.90-6.82 (m, 2H), 6.42 (dd, 1H, J = 17.3 Hz, J = 1.3 Hz), 6.13 (dd, 1H, J = 17.3 Hz, J = 10.4 Hz), 5.84 (dd, 1H, J = 10.4 Hz, J = 1.3 Hz), 4.22 (t, 2H, J = 6.2 Hz), 4.09 (t, 2H, J = 5.5 Hz), 2.12 1.89 (m, 12H).

[0178] Analogously, other phenol derivatives are prepared in the same manner: R means reactant, [P] means product
No.  Yield [%]
8a R

 
  [P]

78
8b R

 
  [P]

69
8c R

 
  [P]

41
8d R

 
  [P]

34
8e R

 
  [P]

70
8f R

 
  [P]

67
8g R

 
  [P]

52
8h R

 
  [P]

61
8i R

 
  [P]

61
8j R

 
  [P]

88
8k R

 
  [P]

32


1H NMR (500 MHz, CDCl3) δ 7.77 (s, 1H), 7.71-7.66 (m, 2H), 7.49-7.42 (m, 3H), 7.41-7.36 (m, 1H), 6.93-6.82 (m, 2H), 6.44 (dd, 1H, J = 17.3 Hz, J = 1.3 Hz), 6.13 (dd, 1H, J = 17.3 Hz, J = 10.5 Hz), 5.88 (dd, 1H, J = 10.5 Hz, J = 1.3 Hz), 4.48 (t, 2H, J = 6.6 Hz), 4.35 (t, 2H, J = 6.7 Hz), 2.73 2.63 (m, 2H), 2.58-2.48 (m, 2H).

1H NMR (500 MHz, CDCl3) δ 7.77 (s, 1H), 7.71-7.69 (m, 2H), 7.47-7.43 (m, 3H), 7.40-7.38 (m, 1H), 6.89-6.87 (m, 2H), 6.14 (s, 1H), 5.62-5.59 (m, 1H), 4.46 (t, 2H, J = 6.5 Hz), 4.35 (t, 2H, J = 6.7 Hz), 2.73 2.63 (m, 2H), 2.57-2.47 (m, 2H).

Example 9:


General remarks & general synthetic procedures (GSP 9) for the solvent polymerization of the monomers:



[0179] The corresponding monomer is dissolved in dry N,N-dimethylformamide in a Schlenck-tube with a stirring bar. The solution is degassed performing three times freeze-evacuate-thaw cycles. After that, azoisobutyronitrile (AIBN, 0.05 equiv.) is added in one portion to the degassed solution, which is heated up to 65 °C in an oil bath for a minimum of three days. The solution is cooled to room temperature and is then poured dropwise into cold methanol (100 ml methanol / 100 mg monomer) while stirring. The precipitated polymer is collected on a frit or the solution is centrifuged several times to obtain the final polymer material.

[0180] Examples of polymers within this invention are given in the following table:
MonomerPolymer





































Examples of application:


Example 10 - General bulk polymerization procedure to produce blank



[0181] A composition of 2-methyl-acrylic acid 2,2,3,3,4,4-hexafluoro-5-(3-phenyl-coumarin-7-yloxy)-pentyl ester (M-07) (8.00 g; 16 mmol), initiator azobisisobutyronitrile (0.04 eq) and crosslinker ethylene glycol dimethacrylate (0.1 - 0.4 eq) in different ratios is degassed by three freeze-pump-thaw cycles.

[0182] Two glass plates are coated with a polyethylene sheet and a 0.5 mm thick cell is created between the polyethylene sheets using a silicone rubber gasket. The coated faces of the glass sheets are clipped together using spring clips with a syringe needle being placed between the gasket and the polyethylene sheets. The cavity is then filled with the above formulation through the needle using a gastight syringe. Once the cavity is filled the syringe needle is removed, a final clip is used to seal the mould and the assembly is placed in an oven at 60°C for 24 hours before the oven is ramped to a temperature of 90°C for a period of 3 hours. The moulds are allowed to cool to room temperature before the film is removed from the mould.

Examples directed to the properties of the compounds


Example 11 - photoinduced refractive index change and glass transition temperature



[0183] The phase transition temperatures are determined with a TA Instruments Q2000 differential scanning calorimeter during heating in the second heating run with 20 K/min from -100 °C to 200 °C in a hermetic aluminium pans. Irradiations of the blanks are performed with a Coherent Avia 355-7000 UV-Laser.

[0184] Common photoactive polymers that undergo refractive index change upon irradiation with UV-light exhibit glass transition temperatures as low as 34°C.

[0185] Polymer films for refractive index measurements are prepared by spin coating or drop casting from 1-8 wt% solutions of the polymers in chloroform onto silicon wafers or quartz plates. For production of bulk polymer blanks, the monomers are melted under vacuum. Appropriate amounts of a radical initiator and cross-linker are mixed in and quickly filled into a heated polymerization chamber. Cross-linked polymer plates are obtained.

[0186] Refractive index change is induced by irradiation at 340 - 365 nm. The refractive indices (n) of the polymer films and blanks at 590 nm are measured on Schmidt+Haensch AR12 before and after irradiation. The following table shows the refractive indices before and after irradiation as well as the change in refractive index (max. Δn).
Polymer NoTg [°C]nΔn
P-046 19,5 1,560 0,021
P-105 37,9 1,579 0,022
P-141 41,7 1,573 0,026



Claims

1. Compounds of formula (I')

wherein

X is O, S or NR0,

X0 is O or S,

Y is O, S or a bond,

-[B]- is selected from the group consisting of formulae (B-1), (B-3), (B-8) and (B-9),



R is at each occurrence independently selected from the group consisting of H, F, a linear or branched alkyl group having 1 to 4 C atoms or a linear or branched partially or fully fluorinated alkyl group having 1 to 4 C atoms,

R' is at each occurrence independently selected from the group consisting of H, F, a linear or branched, non-halogenated, partially or completely halogenated alkyl group having 1 to 20 C atoms, a non-halogenated, partially or completely halogenated cycloalkyl group having 3 to 6 C atoms, a linear or branched, non-halogenated, partially or completely halogenated alkoxy group having 1 to 20 C atoms, a linear or branched, non-halogenated, partially or completely halogenated thioalkyl group having 1 to 20 C atoms,

R0 is at each occurrence independently selected from the group consisting of a linear or branched alkyl group having 1 to 10 C atoms or a cycloalkyl group having 3 to 6 C atoms,

R1 is a polymerizable group of formula (5),

(5-1) which is selected from alkenyl groups of formulae (5-1) and (5-2)



-R2- is -(C(R)2)o-, or -(C(R)2)p-X8-(C(R)2)q-(X9)s-(C(R)2)r-(X10)t-(C(R)2)u-, wherein at least one R is F or a linear or branched partially or fully fluorinated alkyl group having 1 to 4 C atoms,
or a cycloalkylene group having 5 or 6 C atoms which is substituted with at least one R which is F or a linear or branched partially or fully fluorinated alkyl group having 1 to 4 C atoms,

o is selected from the group consisting of 1 to 20,

X8, X9, X10 are at each occurrence independently O, S or NR0,

s, t is 0 or 1,

p, q are at each occurrence independently selected from the group consisting of 1 to 10,

r, u are at each occurrence independently selected from the group consisting of 0 to 10, wherein the overall number of atoms for -(C(R)2)p-X8-(C(R)2)q-(X9)s-(C(R)2)r-(X10)t-(C(R)2)u- is up to 20 atoms,

R3, R4, R5, R6 are at each occurrence independently R',

R7 is R'.


 
2. Compounds according to claim 1 wherein at least one R' within formulae (B-1), (B-3), (B-8) and (B-9) is not H.
 
3. Compounds according to claim 1 or 2 wherein -R2- is -(C(R)2)o-, wherein at least one R is F or a linear or branched partially or fully fluorinated alkyl group having 1 to 4 C atoms or -(C(R)2)p-X8-(C(R)2)q-(X9)s-(C(R)2)r-(X10)t-(C(R)2)u-, wherein at least one R is F or a linear or branched partially or fully fluorinated alkyl group having 1 to 4 C atoms and R, o, X8, X9, X10, p, q, r, s, t and u have a meaning as indicated in claim 1.
 
4. Compounds according to claim 2 wherein R7 is not H.
 
5. Compounds according to one or more of claims 1 to 4 wherein X is O or S.
 
6. Compounds according to one or more of claims 1 to 4 wherein X0 is O and X is O or S.
 
7. Compounds according to one or more of claims 1 to 4 wherein X is O and X0 is O.
 
8. Oligomer or polymer comprising polymerized compounds of formula (I') as described in one or more of claims 1 to 7.
 
9. Polymer according to claim 8 which is a homopolymer, statistical co-polymer, random co-polymer, alternating co-polymer and/or block co-polymer.
 
10. Polymer according to claim 8 which is a co-polymer comprising one or more polymerized compounds of formula (I') as described in one or more of claims 1 to 7 or a constitutional unit M0 of formula (5-p-1),

wherein -R2-, Y, R3, R4, R5, R6, X, X0, -[B]-, R7, X11, R8, R9, R10 and c have a meaning according to one or more of claims 1 to 7 and one or more constitutional units M2, which may be the same or different from one another and are chemically different from the units M0.
 
11. Co-polymer according to claim 10 wherein said one or more constitutional units M2 are derived by polymerization of one or more monomers selected from the group consisting of styrene, ethoxyethyl methacrylate (EOEMA), methyl methacrylate (MMA), n-alkyl acrylates (the n-alkyl group comprising 2-20 C-atoms), n-alkyl methacrylates (the n-alkyl group comprising 2-20 C-atoms), ethoxyethoxy ethylacrylate (EEEA), 2-hydroxyethyl methacrylate (HEMA), tetrahydrofuryl methacrylate (THFMA), glycidylmethacrylate (GMA), 16-hydroxyhexadecyl acrylate, 16-hydroxyhexadecyl methacrylate, 18-hydroxyoctadecyl acrylate, 18-hydroxyoctadecyl methacrylate, 2-phenoxyethyl acrylate (EGPEA), Bisphenol A diacrylate-1 EO/Phenol (BPADA), 2-[3'-2'H-benzotriazol- 2'-yl)-4'-hydroxyphenyl]ethyl methacrylate (BTPEM).
 
12. Composition comprising at least one compound of formula (I') according to one or more of claims 1 to 7.
 
13. Article comprising at least one polymerized compound of formula (I') according to one or more of claims 1 to 7 or at least one oligomer or polymer according to claims 8 to 11.
 
14. Article according to claim 13 wherein said article is a blank which may be transformed into an eye implant or an eye implant, preferably an intraocular lens.
 
15. Process of forming an article of claim 13 or 14, said process comprising the steps of

- providing a composition comprising at least one compound of formula (I') according to one or more of claims 1 to 7 ;

- subsequently forming the article of said composition.


 
16. Process of changing the optical properties of an article according to claim 13 or 14, said process comprising the steps of

- providing an article according to claim 13 or 14, and

- subsequently exposing said article to irradiation having a wavelength of at least 200 nm and at most 1500 nm.


 


Ansprüche

1. Verbindungen der Formel (I')

bei der

X O, S oder NR0 ist,

X0 O oder S ist,

Y O, S oder eine Bindung ist,

-[B]- aus der Gruppe bestehend aus den Formeln (B-1), (B-3), (B-8) und (B-9),



ausgewählt ist,

R bei jedem Auftreten unabhängig ausgewählt ist aus der Gruppe bestehend aus H, F, einer linearen oder verzweigten Alkylgruppe mit 1 bis 4 C-Atomen oder einer linearen oder verzweigten teilweise oder voll fluorierten Alkylgruppe mit 1 bis 4 C-Atomen,

R' bei jedem Auftreten unabhängig ausgewählt ist aus der Gruppe bestehend aus H, F, einer linearen oder verzweigten, nicht, teilweise oder vollständig halogenierten Alkylgruppe mit 1 bis 20 C-Atomen, einer nicht, teilweise oder vollständig halogenierten Cycloalkylgruppe mit 3 bis 6 C-Atomen, einer linearen oder verzweigten, nicht, teilweise oder vollständig halogenierten Alkoxygruppe mit 1 bis 20 C-Atomen, einer linearen oder verzweigten, nicht, teilweise oder vollständig halogenierten Thioalkylgruppe mit 1 bis 20 C-Atomen,

R0 bei jedem Auftreten unabhängig ausgewählt ist aus der Gruppe bestehend aus einer linearen oder verzweigten Alkylgruppe mit 1 bis 10 C-Atomen oder einer Cycloalkylgruppe mit 3 bis 6 C-Atomen,

R1 eine polymerisierbare Gruppe der Formel (5)

ist, die aus Alkenylgruppen der Formeln (5-1) und (5-2)

-R2- -(C(R)2)o- oder -(C(R)2)p-X8-(C(R)2)q-(X9)s-(C(R)2)r-(X10)t-(C(R)2)u-, bei denen mindestens ein R F oder eine lineare oder verzweigte teilweise oder voll fluorierte Alkylgruppe mit 1 bis 4 C-Atomen ist,
oder eine Cycloalkylengruppe mit 5 oder 6 C-Atomen ist, die mit mindestens einem R substituiert ist, das F oder eine lineare oder verzweigte teilweise oder voll fluorierte Alkylgruppe mit 1 bis 4 C-Atomen ist,

o aus der Gruppe bestehend aus 1 bis 20 ausgewählt ist,

X8, X9, X10 bei jedem Auftreten unabhängig O, S oder NR0 sind,

s, t 0 oder 1 ist,

p, q bei jedem Auftreten unabhängig aus der Gruppe bestehend aus 1 bis 10 ausgewählt sind,

r, u bei jedem Auftreten unabhängig aus der Gruppe bestehend aus 0 bis 10 ausgewählt sind, wobei die Gesamtzahl der Atome für -(C(R)2)p-X8-(C(R)2)q-(X9)s-(C(R)2)r-(X10)t-(C(R)2)u- bis zu 20 Atome beträgt,

R3, R4, R5, R6 bei jedem Auftreten unabhängig R' sind,

R7 R' ist.


 
2. Verbindungen nach Anspruch 1, bei denen mindestens ein R' in den Formeln (B-1), (B-3), (B-8) und (B-9) nicht H ist.
 
3. Verbindungen nach Anspruch 1 oder 2, bei denen -R2- -(C(R)2)o- ist, bei dem mindestens ein R F oder eine lineare oder verzweigte teilweise oder voll fluorierte Alkylgruppe mit 1 bis 4 C-Atomen ist, oder -(C(R)2)p-X8-(C(R)2)q-(X9)s-(C(R)2)r-(X10)t-(C(R)2)u- ist, bei dem mindestens ein R F oder eine lineare oder verzweigte teilweise oder voll fluorierte Alkylgruppe mit 1 bis 4 C-Atomen ist, und R, o, X8, X9, X10, p, q, r, s, t und u eine wie in Anspruch 1 angegebene Bedeutung besitzen.
 
4. Verbindungen nach Anspruch 2, bei denen R7 nicht H ist.
 
5. Verbindungen nach einem oder mehreren der Ansprüche 1 bis 4, bei denen X O oder S ist.
 
6. Verbindungen nach einem oder mehreren der Ansprüche 1 bis 4, bei denen X0 O ist und X O oder S ist.
 
7. Verbindungen nach einem oder mehreren der Ansprüche 1 bis 4, bei denen X O ist und X0 O ist.
 
8. Oligomer oder Polymer enthaltend polymerisierte Verbindungen der Formel (I') wie in einem oder mehreren der Ansprüche 1 bis 7 beschrieben.
 
9. Polymer nach Anspruch 8, bei dem es sich um ein Homopolymer, statistisches Copolymer, zufällig verteiltes Copolymer, alternierendes Copolymer und/oder Blockcopolymer handelt.
 
10. Polymer nach Anspruch 8, bei dem es sich um ein Copolymer enthaltend eine oder mehrere polymerisierte Verbindungen der Formel (I') wie in einem oder mehreren der Ansprüche 1 bis 7 beschrieben oder eine konstitutionelle Einheit M0 der Formel (5-p-1),

bei der -R2-, Y, R3, R4, R5, R6, X, X0, -[B]-, R7, X11, R8, R9, R10 und c eine Bedeutung nach einem oder mehreren der Ansprüche 1 bis 7 besitzen, und eine oder mehrere konstitutionelle Einheiten M2, die gleich oder voneinander verschieden sein können und von den Einheiten M0 chemisch verschieden sind, handelt.
 
11. Copolymer nach Anspruch 10, bei dem sich die eine oder mehreren konstitutionellen Einheiten M2 durch Polymerisierung ableiten von einem oder mehreren Monomeren, die ausgewählt sind aus der Gruppe bestehend aus Styrol, Ethoxyethyl-methacrylat (EOEMA), Methyl-methacrylat (MMA), n-Alkyl-acrylate (wobei die n-Alkylgruppe 2-20 C-Atome enthält), n-Alkyl-methacrylate (wobei die n-Alkylgruppe 2-20 C-Atome enthält), Ethoxyethoxy-ethylacrylat (EEEA), 2-Hydroxyethyl-methacrylat (HEMA), Tetrahydrofuryl-methacrylat (THFMA), Glycidylmethacrylat (GMA), 16-Hydroxyhexadecyl-acrylat, 16-Hydroxyhexadecyl-methacrylat, 18-Hydroxyoctadecyl-acrylat, 18-Hydroxyoctadecyl-methacrylat, 2-Phenoxyethyl-acrylat (EGPEA), Bisphenol-A-diacrylat-1 EO/Phenol (BPADA), 2-[3'-2'H-Benzotriazol- 2'-yl)-4'-hydroxyphenyl]ethyl-methacrylat (BTPEM).
 
12. Zusammensetzung enthaltend mindestens eine Verbindung der Formel (I') nach einem oder mehreren der Ansprüche 1 bis 7.
 
13. Gegenstand enthaltend mindestens eine polymerisierte Verbindung der Formel (I') nach einem oder mehreren der Ansprüche 1 bis 7 oder mindestens ein Oligomer oder Polymer nach den Ansprüchen 8 bis 11.
 
14. Gegenstand nach Anspruch 13, bei dem es sich bei dem Gegenstand um einen Rohling, der in ein Augenimplantat umgewandelt werden kann, oder ein Augenimplantat, vorzugsweise eine Intraokularlinse, handelt.
 
15. Verfahren zur Bildung eines Gegenstandes des Anspruchs 13 oder 14, wobei das Verfahren die Schritte

- Bereitstellen einer Zusammensetzung enthaltend mindestens eine Verbindung der Formel (I') nach einem oder mehreren der Ansprüche 1 bis 7;

- anschließendes Bilden des Gegenstandes aus der Zusammensetzung

umfasst.
 
16. Verfahren zur Änderung der optischen Eigenschaften eines Gegenstandes nach Anspruch 13 oder 14, wobei das Verfahren die Schritte

- Bereitstellen eines Gegenstandes nach Anspruch 13 oder 14 und

- anschließendes Belichten des Gegenstandes mit Strahlung mit einer Wellenlänge von mindestens 200 nm und höchstens 1500 nm

umfasst.
 


Revendications

1. Composés de formule (I')

dans lesquels

X est O, S ou NR0,

X0 est O ou S,

Y est O, S ou une liaison,

-[B]- est choisi dans le groupe constitué par les formules (B-1), (B-3), (B-8) et (B-9),



R est choisi indépendamment à chaque occurrence dans le groupe constitué par H, F, un groupement alkyle linéaire ou ramifié ayant de 1 à 4 atomes de C ou un groupement alkyle linéaire ou ramifié partiellement ou totalement fluoré ayant de 1 à 4 atomes de C,

R' est choisi indépendamment à chaque occurrence dans le groupe constitué par H, F, un groupement alkyle linéaire ou ramifié, non halogéné, partiellement ou complètement halogéné ayant de 1 à 20 atomes de C, un groupement cycloalkyle non halogéné, partiellement ou complètement halogéné ayant de 3 à 6 atomes de C, un groupement alcoxy linéaire ou ramifié, non halogéné, partiellement ou complètement halogéné ayant de 1 à 20 atomes de C, un groupement thioalkyle linéaire ou ramifié, non halogéné, partiellement ou complètement halogéné ayant de 1 à 20 atomes de C,

R0 est choisi indépendamment à chaque occurrence dans le groupe constitué par un groupement alkyle linéaire ou ramifié ayant de 1 à 10 atomes de C ou un groupement cycloalkyle ayant de 3 à 6 atomes de C,

R1 est un groupement polymérisable de formule (5),

qui est choisi parmi les groupements alcényle de formules (5-1) et (5-2)



-R2- est -(C(R)2)o-, ou -(C(R)2)p-X8-(C(R)2)q-(X9)s-(C(R)2)r-(X10)t-(C(R)2)u-, où au moins un R est F ou un groupement alkyle linéaire ou ramifié partiellement ou totalement fluoré ayant de 1 à 4 atomes de C,
ou un groupement cycloalkylène ayant 5 ou 6 atomes de C qui est substitué par au moins un R qui est F ou un groupement alkyle linéaire ou ramifié partiellement ou totalement fluoré ayant de 1 à 4 atomes de C,

o est choisi dans le groupe constitué par de 1 à 20,

X8, X9, X10 sont indépendamment à chaque occurrence O, S ou NR0,

s, t vaut 0 ou 1,

p, q sont choisis indépendamment à chaque occurrence dans le groupe constitué par de 1 à 10,

r, u sont choisis indépendamment à chaque occurrence dans le groupe constitué par de 0 à 10, où le nombre global d'atomes pour -(C(R)2)p-X8-(C(R)2)q-(X9)s-(C(R)2)r-(X10)t-(C(R)2)u- va jusqu'à 20 atomes,

R3, R4, R5, R6 sont indépendamment à chaque occurrence R',

R7 est R'.


 
2. Composés selon la revendication 1, dans lesquels au moins un R' au sein des formules (B-1), (B-3), (B-8) et (B-9) n'est pas H.
 
3. Composés selon la revendication 1 ou 2, dans lesquels -R2- est -(C(R)2)o-, où au moins un R est F ou un groupement alkyle linéaire ou ramifié partiellement ou totalement fluoré ayant de 1 à 4 atomes de C ou -(C(R)2)p-X8-(C(R)2)q-(X9)s-(C(R)2)r-(X10)t-(C(R)2)u-, où au moins un R est F ou un groupement alkyle linéaire ou ramifié partiellement ou totalement fluoré ayant de 1 à 4 atomes de C et R, o, X8, X9, X10, p, q, r, s, t et u revêtent une signification telle qu'indiquée selon la revendication 1.
 
4. Composés selon la revendication 2, dans lesquels R7 n'est pas H.
 
5. Composés selon l'une ou plusieurs parmi les revendications 1 à 4, dans lesquels X est O ou S.
 
6. Composés selon l'une ou plusieurs parmi les revendications 1 à 4, dans lesquels X0 est O et X est O ou S.
 
7. Composés selon l'une ou plusieurs parmi les revendications 1 à 4, dans lesquels X est O et X0 est O.
 
8. Oligomère ou polymère comprenant des composés polymérisés de formule (I') tel que décrit selon l'une ou plusieurs parmi les revendications 1 à 7.
 
9. Polymère selon la revendication 8, qui est un homopolymère, un copolymère statistique, un copolymère aléatoire, un copolymère alterné et/ou un copolymère bloc.
 
10. Polymère selon la revendication 8, qui est un copolymère comprenant un ou plusieurs composés de formule (I') polymérisés tel que décrit selon l'une ou plusieurs parmi les revendications 1 à 7 ou un motif constitutionnel M0 de formule (5-p-1),

où -R2-, Y, R3, R4, R5, R6, X, X0, -[B]-, R7, X11, R8, R9, R10 et c revêtent une signification selon l'une ou plusieurs parmi les revendications 1 à 7 et un ou plusieurs motifs constitutionnels M2, qui peuvent être identiques ou différents les uns des autres et sont chimiquement différents des motifs M0.
 
11. Copolymère selon la revendication 10, dans lequel lesdits un ou plusieurs motifs constitutionnels M2 sont dérivés par polymérisation d'un ou plusieurs monomères choisis dans le groupe constitué par le styrène, le méthacrylate d'éthoxyéthyle (EOEMA), le méthacrylate de méthyle (MMA), les acrylates de n-alkyle (le groupement n-alkyle comprenant 2-20 atomes de C), les méthacrylates de n-alkyle (le groupement n-alkyle comprenant 2-20 atomes de C), l'éthylacrylate d'éthoxyéthoxy (EEEA), le méthacrylate de 2-hydroxyéthyle (HEMA), le méthacrylate de tétrahydrofuryle (THFMA), le méthacrylate de glycidyle (GMA), l'acrylate de 16-hydroxyhexadécyle, le méthacrylate de 16-hydroxyhexadécyle, l'acrylate de 18-hydroxyoctadécyle, le méthacrylate de 18-hydroxyoctadécyle, l'acrylate de 2-phénoxyéthyle (EGPEA), le diacrylate de Bisphénol A -1 OE/Phénol (BPADA), le méthacrylate de 2-[3'-2'H-benzotriazol- 2'-yl)-4'-hydroxyphényl]éthyle (BTPEM).
 
12. Composition, comprenant au moins un composé de formule (I') selon l'une ou plusieurs parmi les revendications 1 à 7.
 
13. Article comprenant au moins un composé de formule (I') polymérisé selon l'une ou plusieurs parmi les revendications 1 à 7 ou au moins un oligomère ou polymère selon les revendications 8 à 11.
 
14. Article selon la revendication 13, ledit article étant une ébauche qui peut être transformée en un implant oculaire ou un implant oculaire, préférablement une lentille intraoculaire.
 
15. Procédé de façonnage d'un article selon la revendication 13 ou 14, ledit procédé comprenant les étapes consistant à

- mettre à disposition une composition comprenant au moins un composé de formule (I') selon l'une ou plusieurs parmi les revendications 1 à 7 ;

- façonner ensuite l'article de ladite composition.


 
16. Procédé de modification des propriétés optiques d'un article selon la revendication 13 ou 14, ledit procédé comprenant les étapes consistant à

- mettre à disposition un article selon la revendication 13 ou 14, et

- exposer ensuite ledit article à un rayonnement ayant une longueur d'onde d'au moins 200 nm et d'au plus 1500 nm.


 






Cited references

REFERENCES CITED IN THE DESCRIPTION



This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description




Non-patent literature cited in the description